HIV vaccine and how to use it

Abstract

To provide HIV vaccines and methods of using.SOLUTION: Provided are HIV-1 fusion polypeptides, polynucleotides encoding such fusion polypeptides, vectors expressing such fusion polypeptides for use in eliciting an immune response against HIV-1; pharmaceutical and immunogenic compositions and kits comprising such fusion polypeptides, polynucleotides or vectors, and methods of use in treating and / or preventing HIV-1. Further provided are methods for design of antiviral vaccines, including vaccines to elicit an immune response against HIV-1.SELECTED DRAWING: None

Description

[Technical Field]

[0001] (Cross-reference of related applications) This application asserts the interests of U.S. Provisional Patent Applications No. 63 / 137,521 filed 14 January 2021, No. 63 / 149,820 filed 16 February 2021, and No. 63 / 170,900 filed 5 April 2021, pursuant to 35 United States Code § 119(e), which are incorporated herein by reference in their entirety for all purposes. Sequence List

[0002] This application includes an electronically submitted sequence listing in ASCII format, the entirety of which is incorporated herein by reference. The ASCII copy, created on December 12, 2021, is named 1355-WO-PCT.txt and is 512,244 bytes in size. [Background technology]

[0003] HIV remains a leading cause of mobility and mortality worldwide, with over 38 million infections and 690,000 deaths globally in 2019 (UNAIDS.Fact Sheet-World AIDS Day 2020.unaidsorg / en / resources / fact-sheet.2020). Significant improvements have been made in HIV treatment over the past 30 years. The development of highly active antiretroviral therapies has improved survival rates and reduced HIV-related immunosuppression and opportunistic infections in people living with HIV (Johnson, et al., PLoS Med. 2013; 10(4):e1001418; May, et al., AIDS. (2014) 28(8):1193-202; Rodger, et al., AIDS. (2013) 27(6):973-9; Samji, et al., PLoS One. (2013) 8(12):e81355). In recent years, antiretroviral therapy (ART) regimens have been simplified to once-daily long-acting oral pills and, in the near future, injectable therapies (Swindells, et al., N Engl J Med. (2020) 382(12):1112-23; Orkin, et al., N Engl J Med. (2020) 382(12):1124-35; Link, et al., Nature. (2020) 584(7822):614-8). Despite these advances in treatment, to date, only two cases of fully demonstrated cure have been reported, both requiring severe immunosuppression and bone marrow transplantation (Gupta, et al., Lancet HIV. (2020) 7(5):e340-e7; Hutter, et al., N Engl J Med. (2009) 360(7):692-8). Unlike many spontaneously curing infections, the HIV virus integrates itself into the host genome, establishing latent status in quiescent memory CD4+ T cells (Eisele, et al., Immunity. (2012) 37(3):377-88). These cells form an HIV latent reservoir that cannot be eliminated by standard antiretroviral therapy. Reservoir cells are also protected from immune surveillance and clearance mechanisms because they do not express viral antigens that would allow them to evade recognition and clearance by cytotoxic T cells. Despite the reservoir's long lifespan and the detectable decrease in reservoir size, viral rebound is observed after discontinuation of ART (Henrich, et al., Ann Intern Med. (2014) 161(5):319-27; Henrich, et al., J Infect Dis. (2013) 207(11):1694-702). Activation of the reservoir with latent infection reactivators needs to be combined with an effective mechanism to stimulate cytotoxic T cells and eliminate infected reservoir cells (Ait-Ammar, et al., Front Microbiol. (2019) 10:3060; Mothe, et al., Front Immunol. (2020) 11:823; Fidler, et al., Lancet. (2020) 395(10227):888-98). Therapeutic vaccines designed to elicit antigen-specific effector T cell responses could be a further component of HIV cure strategies.

[0004] T-cell vaccines hold considerable promise in the therapeutic field of oncology and other cancers. High levels of tumor-infiltrating CD8+ lymphocytes are associated with a favorable prognosis in several cancers, and there is considerable interest in developing vaccines that can induce tumor-specific cytotoxic CD8+ T cells. While previous approaches have had limited success (Rosenberg, et al., Nature Medicine. (2004) 10(9):909-15), the use of novel delivery platforms and improved techniques in antigen discovery and immunomodulation offer some promise (Ott, et al., Nature. (2017) 547(7662):217-21). Similarly, T cells play a crucial role in controlling HIV viremia. Antigen-specific T cells generated in acute HIV infection are involved in driving the initial decline in viremia (Borrow, et al., J Virol. (1994) 68(9):6103-10; Koup, et al., J Virol. (1994) 68(7):4650-5). Long-term non-progressive human HIV-infected individuals, i.e., elite controllers, are characterized by a robust effective antigen-specific T cell response. In SIV infection (a non-human primate model of human HIV infection), naturally occurring or vaccine-generated antigen-specific T cells are associated with viral control (Schmitz, et al.). al., Science. (1999) 283(5403): 857-60; Jin, et al., J Exp Med. (1999) 189(6): 991-8). Despite this data, T-cell vaccines for prevention have only achieved limited success in inducing a T-cell response of limited range or efficacy (Buchbinder, et al., Lancet. (2008) 372(9653): 1881-93; Janes, et al., J Infect Dis. (2013) 208(8): 1231-9; Excler, et al., Curr Opin HIV AIDS. (2016) 11(6): 607-13). Trials of therapeutic vaccines using T cell vaccines have also shown limited efficacy (Mothe, et al., Front Immunol. (2020) 11:823; Colby, et al., Nature Medicine. (2020) 26(4):498-501). These trials use viral vectors such as adenovirus (human and chimpanzee) and modified vaccinia ankara (MVA) virus with full-length viral antigens or shorter constructs (Barouch, et al., Lancet. (2018) 392(10143):232-43; Mothe, et al., EClinicalMedicine. (2019) 11:65-80). Data from these trials suggest a narrow range of antigen-specific T cells generated after vaccination. While these vaccine-induced T cells secrete IFN-γ in standard ELISpot assays, the lack of demonstrated efficacy suggests that these T cells may not possess full cytotoxic activity.

[0005] The design of immunogens is a component of any therapeutic HIV vaccine to target conserved regions and generate an appropriate antigen-specific response with cytotoxic activity. Natural infection has demonstrated that the immune response tends to concentrate within HIV, for example, in highly immunodominant variable regions in the HIV envelope or Nef, or in variable regions in the HIV Gag (Addo, et al. J Virol. (2003) 77(3):2081-92; Betts, et al., J Virol. 2001; 75(24):11983-91). These responses generate T cells from which the virus can rapidly escape without adaptation costs (Liu, et al., J Virol. (2006) 80(19):9519-29). An effective HIV vaccine needs to drive the establishment of a de novo response that bypasses these regions and concentrates the immune response on conserved regions of the virus that are required to be preserved for the maintenance of viral function. Previous HIV vaccines have primarily focused on designing immunogens that offer universal range by addressing overall HIV viral diversity, adapting algorithms to generate either full-length sequences or constructs of conserved regions (Korber, et al., Hum Vaccin Immunother. (2020) 16(3):713-722; Fischer, et al., Nature Medicine. (2007) 13(1):100-6). All of these approaches primarily evaluate consensus sequences to assess inter-patient variability for determining conserved regions and are concatenated to provide an overall sequence range. However, several circulating pseudospecies exist within individuals infected with HIV. Some of these viral pseudospecies are generated as a result of T cell pressure and reflect existing viral evasion pathways that should lead to a T cell response directed towards the virus (Liu, et al., J Virol. (2006) 80(19): 9519-29; Korber, et al., 2020, supra; Price, et al., Proc Natl Acad Sci US A. (1997) 94(5): 1890-5). The limited effectiveness of previous vaccines may be partly explained by the fact that they did not consider pseudospecies, along with the identification of highly conserved immunogenic regions (Hanke, et al., Expert Rev). Vaccines.(2019)18(10):1029-41). [Prior art documents] [Non-patent literature]

[0006] [Non-Patent Document 1] UNAIDS.Fact Sheet-World AIDS Day 2020.unaidsorg / en / resources / fact-sheet.2020 [Non-Patent Document 2] Johnson,et al.,PLoS Med.2013;10(4):e1001418 [Non-Patent Document 3] May, et al., AIDS.(2014)28(8):1193-202 [Non-Patent Document 4] Rodger,et al.,AIDS.(2013)27(6):973-9 [Non-Patent Document 5] Samji,et al.,PLoS One.(2013)8(12):e81355 [Overview of the project] [Means for solving the problem]

[0007] A fusion polypeptide is provided comprising multiple polypeptide segments of one or more human immunodeficiency virus-1 (HIV-1) proteins encoded by two or more HIV genes selected from gag, pol, and nef. In some embodiments, the multiple polypeptide segments comprise or consist of polypeptide segments encoded by the HIV-1 genes pol and nef, and not polypeptide segments encoded by the HIV-1 genes env, tat, rev, vpr, vif, and / or vpu. In some embodiments, the multiple polypeptide segments comprise or consist of polypeptide segments encoded by the HIV-1 genes gag, pol, and nef, and not polypeptide segments encoded by the HIV-1 genes env, tat, rev, vpr, vif, and / or vpu. In some embodiments, the multiple polypeptide segments are derived from conserved regions in a population of viral proteome sequences. In some embodiments, the conserved region is conserved in over 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of HIV-1 species in the patient population. In some embodiments, the conserved region is conserved among one or more HIV-1 clades A-K, for example, one or more clades A, B, C, D, and G, or one or more recombinant forms of HIV-1 clades A-K, and combinations thereof. In some embodiments, the fusion polypeptide comprises at least four and up to six polypeptide segments, for example, four, five, or six polypeptide segments.In some embodiments, each polypeptide segment is at least 10 amino acid long and up to approximately 225 amino acid long, for example, from at least 10 amino acid long to up to 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37 The amino acid lengths are 38, 39, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, or 225. In some embodiments, the full length of the fusion polypeptide comprises at least about 330 amino acids and up to about 505 amino acids (excluding the signal peptide) or up to about 550 amino acids (including the signal peptide), for example, at least about 330 amino acids and up to about 335, 340, 345, 350, 355, 360, 365, 370, 375, 380, 385, 390, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470, 475, 480, 485, 490, 495, 500, 505, 510, 515, 520, 525, 530, 535, 540, 545, or 550 amino acids. In some embodiments, the total length of the fusion polypeptide is 550 amino acids or less (having a signal peptide) or 505 amino acids or less (not having a signal peptide), for example, 545, 540, 535, 530, 525, 520, 515, 510, 505, 500, 495, 490, 485, 480, 475, 470, 465, 460, 455, 450, 445, 440, 435, 430, 425, 420, 415, 410, 405, 400, 390, 385, 380, 375, 370, 365, 360, 355, 350, 345, 340, 335, or 330 amino acids or less. In some embodiments, the full length of the fusion polypeptide includes at least 350 amino acids and up to 385 amino acids, for example, at least 350 amino acids and up to 365 amino acids.In some embodiments, the full length of the fusion polypeptide contains at least 390 amino acids and up to 395 amino acids. In some embodiments, each polypeptide segment contains or consists of one or more predicted T cell epitopes. In some embodiments, the fusion polypeptide contains three or more predicted T cell epitopes, e.g., four, five, six or more predicted T cell epitopes. In some embodiments, the fusion polypeptide contains one or more polypeptide segments that bind to or present one or more human HLA class I alleles (e.g., alleles 1, 2, 3, 4, 5, or 6) within a single subject or across multiple patients. In some embodiments, the fusion polypeptide contains at least human HLA A. *0201 comprises one or more polypeptide segments that bind to or are presented by an HLA class I molecule. In some embodiments, the fusion polypeptide comprises one or more polypeptide segments that are intracellularly processed and presented by one or more human HLA class II alleles (e.g., alleles 1, 2, 3, 4, 5, or 6) within a single subject, for example. In some embodiments, one or more polypeptide segments are tangent to or fused to adjacent segments. In some embodiments, one or more polypeptide segments are linked to adjacent segments by one or more peptide linkers. In some embodiments, one or more peptide linkers are selected from one or more of polyalanine, polyglycine, Gln-Glu-Glu (QEE), lysine (L), isoleucine (I), Leu-Ile (LI), Lys-Ile-Leu (KIL), Leu-Ile-Lys (LIK), Pro-Pro-Val (PPV), Ser-Glu-Gly (SEG), cleavable linkers, mobile linkers, rigid linkers, and combinations thereof. In some embodiments, the mobile linker is selected from Gln-Glu-Glu (QEE) (SEQ ID NO: 51), lysine (L), isoleucine (I), Leu-Ile (LI), Lys-Ile-Leu (KIL) (SEQ ID NO: 52), Leu-Ile-Lys (LIK) (SEQ ID NO: 53), Pro-Pro-Val (PPV) (SEQ ID NO: 54), and Ser-Glu-Gly (SEG) (SEQ ID NO: 55). In some embodiments, the mobile linker includes, for example, two or three consecutive alanine residues, e.g., AA, AAA (SEQ ID NO: 48), AAY (SEQ ID NO: 49), or AAX (where X is any amino acid (e.g., A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, Y)) (SEQ ID NO: 50), or includes a polyalanine linker or polyglycine linker comprising these. In some embodiments, the movable linker includes or consists of GG, GGS (SEQ ID NO: 57), GSG (SEQ ID NO: 58), or GGGS (SEQ ID NO: 59).In some embodiments, the cleavable linker is selected from 2A cleavable peptides (e.g., foot-and-mouth disease virus (F2A), equine rhinitis A virus (E2A), porcine rhinitis virus-1 (P2A), and Thosea asigna virus (T2A)), furin recognition / cleavage sequences (e.g., RAKR (SEQ ID NO: 60), REKR (SEQ ID NO: 61), and RRKR (SEQ ID NO: 62)), and combinations, derivatives, or variants thereof. In some embodiments, the cleavable linker includes or consists of furin recognition / cleavage sites selected from RAKR (SEQ ID NO: 60), REKR (SEQ ID NO: 61), and RRKR (SEQ ID NO: 62). In some embodiments, the severable linker is attenuated by It contains or consists of amino acid sequences that are 8% or at least 99% identical, and includes or consists of the amino acid sequences ATNFSLLKQAGDVEENPGP (SEQ ID NO: 63), APVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 64), RAKRAPVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 65), QCTNYALLKLAGDVESNPGP (SEQ ID NO: 66), or EGRGSLLTCGDVEENPGP (SEQ ID NO: 67). In some embodiments, the fusion polypeptide comprises two, three, four, five, six, or more polypeptide segments, such that the polypeptide comprises Gag 1-53, Gag 147-369, Pol 56-117, Pol 129-320, Pol 367-431, Pol 542-606, Pol 586-606, Pol 683-708, Pol 747-827, Pol 840-909, Pol 840-920, Pol. It contains or consists of amino acid residues corresponding to 932-1003, Nef 64-76, Nef 64-99, or Nef 117-148, in which case the amino acid position numbers of Gag, Pol, and Nef correspond to SEQ ID NOs. 1, 2, and 3, respectively. In some embodiments, the fusion polypeptide does not include Gag 54-146, Gag 370-500, Pol 1-55, Pol 118-128, Pol 321-366, Pol 432-541, Pol 607-682, Pol 709-746, Pol 828-839, Pol 921-931, Nef 1-63, Nef 100-116, and Nef 149-206, or any polypeptide segments corresponding to these fragments or subsequences, where the amino acid positions of Gag, Pol, and Nef correspond to SEQ ID NOs. 1, 2, and 3, respectively. In some embodiments, the fusion polypeptide does not include a polypeptide segment having any one amino acid sequence of SEQ ID NOs. 35-47, or a fragment or subsequence thereof, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs. In some embodiments, the fusion polypeptide includes two, three, four, five, six, or more polypeptide segments selected from SEQ ID NOs. 4-33.In some embodiments, the fusion polypeptide comprises or consists of the following polypeptide segments, where the amino acid position numbers of Gag, Pol, and Nef correspond to SEQ ID NOs: 1, 2, and 3, respectively: (a) amino acid residues corresponding to Gag 1-53, Gag 147-369, Pol 683-708 and Nef 117-148, (b) amino acid residues corresponding to Pol 56-117, Pol 129-320, Pol 367-431 and Nef 64-99, (c) amino acid residues corresponding to Pol 542-606, Pol 747-827, Pol 840-920, Pol 932-1003 and Nef 64-99, (d) Gag 1-53, Gag 147-369, Pol 683-708, Pol 747-827, Pol (e) Amino acid residues corresponding to 840-920 and Nef 117-148, (f) Amino acid residues corresponding to Pol 56-117, Pol 129-320, Pol 367-431, Pol 542-606, Pol 932-1003 and Nef 64-99, (f) Gag 147-369, Pol 586-606. Amino acid residues corresponding to Pol 683-708 and Pol 840-920, (g)Pol 129-320, Pol 747-827, Pol 932-1003 and Nef Amino acid residues corresponding to 64-76, or (h)Gag:147-369, Pol 747-827, Pol 840-909 and Nef 64-76. In some forms, the fusion polypeptide comprises or consists of the following polypeptide segments: (a) Sequence IDs 4, 6, 18 and 32, or sequence segments identical to Sequence IDs 4, 6, 18 and 32 by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively; (b) Sequence IDs 5, 7, 19 and 33, or sequences identical to Sequence IDs 5, 7, 19 and 33 by at least (c) Sequence segments that are 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical, (c) Sequence numbers 8, 10, 12, and 30, or sequences that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to sequence numbers 8, 10, 12, and 30, respectively (d) Column segments, (d) Sequence segments identical to sequence numbers 9, 11, 13 and 31 by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively, (e) Sequence numbers 14, 20, 24, 26 and 30 by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, respectively, (f) Sequence segments that are 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical, (g) Sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to sequence numbers 15, 21, 25, 27, and 31, respectively, (g) Sequence numbers 4, 6, 18,Sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to sequence numbers 20, 24, and 32, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, respectively, (h) sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, respectively, (i) Sequence segments that are 94%, 95%, 96%, 97%, 98%, or 99% identical to sequence numbers 8, 10, 12, 14, 26, and 30, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to sequence numbers 9, 11, 13, 15, 27, and 31, or sequence segments that are at least identical to sequence numbers 9, 11, 13, 15, 27, and 31, respectively (k) Sequence segments that are 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical, (k) Sequence numbers 6, 16, 18, and 24, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to sequence numbers 6, 16, 18, and 24, respectively, (l) Sequence numbers 7, 17, Sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to (m) Sequences 10, 20, 26, and 28, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,(n) Sequence segments that are 98% or 99% identical to sequence numbers 11, 21, 27 and 29, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to sequence numbers 6, 20, 22 and 28, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, or 8 (p) Sequence segments that are 9%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical, (p) Sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to sequence segments 6, 16, 18, and 24, or at least 80% identical to sequence segments 6, 16, 18, and 24, (r) Sequence segments that are 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical, (r) Sequence numbers 7, 17, 19, and 25, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to sequence numbers 7, 17, 19, and 25, respectively, (s) Sequence numbers 10, 20, 26, and 28, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to sequence numbers 11, 21, 27, and 29, or sequence numbers 11, 21, 27, and 29, respectively, at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,Sequence segments that are 98% or 99% identical. In some forms, the fusion polypeptide comprises or consists of the following polypeptide segments, optionally linked or connected by one or more linkers in the order of N-terminus to C-terminus: SEQ ID NOs. 6, 4, 18, and 32, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 7, 5, 33, and 19, or sequence number Sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to sequence numbers 7, 5, 33, and 19, respectively, sequence numbers 12, 30, 8, and 10, or sequence numbers that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to sequence numbers 12, 30, 8, and 10, respectively. A sequence segment, sequence numbers 9, 31, 13 and 11, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to sequence numbers 14, 26, 20, 30 and 24, or sequence numbers 14, 26, 20, 30 and 24, respectively, are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 9 Sequence segments that are 1%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical, sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to sequence segments 32, 18, 4, and 6, or sequence segments that are at least 80%, 81%, or 99% identical to sequence segments 32, 18, 4, and 6,Sequence segments that are 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical, sequence numbers 7, 33, 5, and 19, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to sequence numbers 7, 33, 5, and 19, respectively, sequence numbers 8, 30, 12, and 10, or sequence numbers 8, 30, Sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to sequence numbers 13, 31, 9, and 11, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to sequence numbers 12 and 10, respectively, Sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to sequence numbers 26, 30, 14, 20, and 24, respectively; sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93% identical to sequence numbers 31, 27, 15, 25, and 21, respectively; sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93% identical to sequence numbers 31, 27, 15, 25, and 21, respectively. Sequence segments that are identical by %, 94%, 95%, 96%, 97%, 98%, or 99%, to sequence numbers 24, 6, 4, 20, 18, and 32, or sequence segments that are identical by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, to sequence numbers 6, 20, 4, 24, 32, and 18, or sequence numbers 6, 20, 4, 24, 32, and 18, respectively,82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、 , sequence segments that are 94%, 95%, 96%, 97%, 98%, or 99% identical, sequence numbers 7, 21, 5, 25, 33, and 19, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to sequence numbers 8, 30, 14, 12, 26, and 10, or sequence numbers 8, 30, 14, 12, 26, and 10, respectively at least 80%, 81% , Sequence segments identical to 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, Sequence IDs 8, 12, 30, 26, 14, and 10, or Sequence segments identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, Sequence IDs 9, 13, 31, Sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to sequence numbers 27, 15, and 11, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, or 94% identical to sequence numbers 20, 32, 24, 4, 6, and 18, respectively. , sequence segments that are 95%, 96%, 97%, 98%, or 99% identical, sequence numbers 7, 25, 19, 5, 33, and 21, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to sequence numbers 26, 30, 12, 14, 8, and 10, or sequence numbers 26, 30, 12, 14, 8, and 10, at least 80%, 81%, 82%,Sequence segments that are 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical, sequence numbers 15, 31, 9, 27, 13, and 11, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to sequence numbers 15, 31, 9, 27, 13, and 11, respectively, sequence numbers 24, 6, 16, and 18, Or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to sequence numbers 24, 6, 16, and 18, respectively, sequence segments 7, 19, 17, and 25, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to sequence numbers 7, 19, 17, and 25, respectively. A sequence segment, sequence numbers 24, 16, 6, and 18, or a sequence segment, sequence numbers 7, 25, 17, and 19, which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to sequence numbers 24, 16, 6, and 18, respectively, is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, or 94% identical to sequence numbers 7, 25, 17, and 19, respectively. Sequence segments that are 95%, 96%, 97%, 98%, or 99% identical, sequence numbers 26, 20, 10, and 28, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to sequence numbers 21, 27, 11, and 29, or sequence numbers 21, 27, 11, and 29, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, or 86% identical to sequence numbers 21, 27, 11, and 29,Sequence segments that are 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical, sequence numbers 26, 10, 20, and 28, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to sequence numbers 26, 10, 20, and 28, respectively, sequence numbers 11, 27, 21, and 29, or Sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to sequence segments 11, 27, 21, and 29, respectively; sequence segments 22, 6, 20, and 28, or sequence segments 22, 6, 20, and 28, respectively, are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 9 Sequence segments that are 5%, 96%, 97%, 98%, or 99% identical, sequence numbers 23, 7, 21, and 29, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to sequence numbers 22, 20, 6, and 28, or sequence numbers that are at least 80%, 81%, 82% identical to sequence numbers 22, 20, 6, and 28, respectively. Sequence segments that are identical by %, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively, or sequence segments that are identical by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% to sequence numbers 7, 21, 23, and 29, respectively. In some embodiments, the fusion polypeptide is one amino acid sequence of any of SEQ ID NOs. 70-101, 105-112, 200-209, 222-223, and 227, or SEQ ID NOs. 70-101, 105-112,It contains, or consists of, an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of 200-209, 222-223, and 227. In some embodiments, the fusion polypeptide contains, or comprises, an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of the amino acid sequences 82-83, 85-87, 98-101, 209, and 222-223.

[0008] A complex fusion polypeptide is further provided, comprising at least a first fusion polypeptide and a second fusion polypeptide, wherein the first and second fusion polypeptides are independently selected from the fusion polypeptides described above and herein. In some embodiments, the complex fusion polypeptide comprises, or consists of, the following first and second fusion polypeptides optionally linked or connected by one or more linkers: Sequence IDs 70 and 71, or any one of Sequence IDs 70 and 71, which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to each other. Fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to each of Sequence IDs 72 and 73, respectively, fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, or 8% identical to each of Sequence IDs 74 and 75, respectively A fusion polypeptide that is 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 76 and 77, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 76 and 77, or SEQ ID NOs. 78 and 79 A fusion polypeptide, SEQ ID NOs. 80 and 81, which are identical to any one of the following by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively, or a fusion polypeptide, SEQ ID NOs. 80 and 81, which are identical to any one of the following by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,Fusion polypeptides that are 98% or 99% identical to SEQ ID NOs. 82 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 84 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 A fusion polypeptide that is identical to 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of SEQ ID NOs. 86 and 87, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of either SEQ ID NOs. 88 and 89, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, 84%, or 8 Fusion polypeptides that are 5%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 82 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 82 and 8695%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 82 and 86 Fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical, SEQ ID NOs. 82 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 82 or 88, respectively, SEQ ID NOs. 83 and 87,Or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 83 and 87, respectively; SEQ ID NOs. 85 and 87; or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 85 and 87, respectively. A fusion polypeptide that is identical to SEQ ID NOs. 88 and 87, or one of SEQ ID NOs. 88 and 87 by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively, a fusion polypeptide that is identical to SEQ ID NOs. 84 and 88, or one of SEQ ID NOs. 84 and 88, by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, or 95%. A fusion polypeptide that is identical to 96%, 97%, 98%, or 99% of SEQ ID NOs. 85 and 89, or SEQ ID NOs. 85 and 101, and each of these, is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a fusion polypeptide that is identical to SEQ ID NOs. 85 and 89, or SEQ ID NOs. 85 and 101, and each of these, is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, or 89% identical to a fusion polypeptide that is identical to 96%, 97%, 98%, or 99% A fusion polypeptide that is identical to %, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 90 and 91, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 92 and 93, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, or a fusion polypeptide that is identical to at least 9Fusion polypeptides that are 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 96 and 97 Fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical, SEQ ID NOs. 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 94 or 96, respectively, SEQ ID NOs. 95 and 97, and , A fusion polypeptide that is identical to SEQ ID NOs. 98 and 100, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 99 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, or 93% identical to either SEQ ID NOs. 99 and 101,A fusion polypeptide that is 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 98 and 99, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 100 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. In some embodiments, the complex fusion polypeptide comprises or consists of the following first and second fusion polypeptides, optionally linked or connected from the N-terminus to the C-terminus by one or more linkers: a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 70 or SEQ ID NOs. 71 and 70, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, or 99% identical to either A fusion polypeptide that is 2%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 72 and 73, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or any one of SEQ ID NOs. 72 and 73. 99% identical fusion polypeptides, SEQ ID NOs. 73 and 72, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 73 or 72, respectively, SEQ ID NOs. 74 and 75,or a fusion polypeptide which is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 74 or SEQ ID NOs. 75 and 74, or at least 8 of each of SEQ ID NOs. 75 and 74, Fusion polypeptides identical to 0%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 76 and 77, or fusion polypeptides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively, SEQ ID NOs. 77 and 76, or SEQ ID NOs. 7 Fusion polypeptides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of either 7 or 76, SEQ ID NOs. 78 and 79, or fusion polypeptides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of either SEQ ID NOs. 78 and 79, respectively. Plitter, fusion polypeptides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of either SEQ ID NOs. 80 and 81, or fusion polypeptides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, or 97% of either SEQ ID NOs. 80 and 81, respectively. A fusion polypeptide that is 98% or 99% identical to SEQ ID NOs. 81 and 80, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 82 and 83, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, or 91% identical to either SEQ ID NOs. 82 and 83,Fusion polypeptides that are 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 83 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 84 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, or 86% identical to92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. A fusion polypeptide that is identical to 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 85 and 84, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 86 and 87, or a fusion polypeptide that is identical to at least 80% to one of SEQ ID NOs. 86 and 87, Fusion polypeptides identical to 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 87 and 86, or fusion polypeptides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively, SEQ ID NOs. 88 and 89, or SEQ ID NOs. 88 and 89 A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of the 9, SEQ ID NOs. 89 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of the 9, SEQ ID NOs. 89 and 88,A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 82 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or identical to SEQ ID NOs. 85 and 82, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical fusion polypeptide, SEQ ID NOs. 82 and 86, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical fusion polypeptide, SEQ ID NOs. 86 and 82, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, Fusion polypeptides that are 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 82 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 88 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91% identical to SEQ ID NOs. 88 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91% identical to SEQ ID NOs. A fusion polypeptide that is identical to %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 83 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 87 and 83, or at least 80%, 81%, 82%, 83%, 84%, 85%,Fusion polypeptides that are 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 85 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 87 and 85, or fusion polypeptides that are at least 80% identical to either SEQ ID NOs. 87 and 85, or fusion polypeptides that are at least 80% identical to either SEQ ID NOs. 87 and 85. Fusion polypeptides identical to %, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 88 and 87, or fusion polypeptides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively, SEQ ID NOs. 87 and 88, or SEQ ID NOs. 87 and A fusion polypeptide which is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 84 and 88, or a fusion polypeptide which is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 88 and 84. D, a fusion polypeptide identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of either SEQ ID NOs. 85 and 89, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,A fusion polypeptide that is 98% or 99% identical to SEQ ID NOs. 89 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 85 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 9 A fusion polypeptide that is 1%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 101 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 90 and 91, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, or 84% identical to either SEQ ID NOs. 90 and 91. , fusion polypeptides identical to 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of SEQ ID NOs. 91 and 90, or fusion polypeptides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of either SEQ ID NOs. 92 and 936%, 95%, 96%, 97%, 98%, or 99% of either SEQ ID NOs. 92 and 93, Fusion polypeptides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 93 and 92, or fusion polypeptides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 94 and 95,or a fusion polypeptide which is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NO: 94 or 95, SEQ ID NO: 95, A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 96 and 97, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or Fusion polypeptides that are 99% identical, SEQ ID NOs. 97 and 96, or any one of SEQ ID NOs. 97 and 96, and each fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical, SEQ ID NOs. 94 and 96, or any one of SEQ ID NOs. 94 and 96, and each fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 9 Fusion polypeptides that are 4%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 96 and 94, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, or 88% identical to A fusion polypeptide that is identical to %, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 97 and 95, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 220 and 221, or a fusion polypeptide that is identical to at least 80%, 81%,0%, or a fusion polypeptide that is identical to at least 80%, 80%, or a fusion polypeptide that is identical to at least 80%, 80%, or a fusion polypeptide that is identical to at least 80%, 80%, or a fusion polypeptide that is identical to at least 80%, 80%, or a fusion polypeptide that is identical to at leastFusion polypeptides identical to 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 221 and 220, or fusion polypeptides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 98 and 100, or SEQ ID NOs. 98 and A fusion polypeptide which is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of 100, SEQ ID NOs. 100 and 98, or a fusion polypeptide which is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of Plitter, fusion polypeptides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of either SEQ ID NOs: 99 or 101, fusion polypeptides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, or 96% of either SEQ ID NOs: 101 or 99, fusion polypeptides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, or 96% of either SEQ ID NOs: 101 or 99 A fusion polypeptide that is 97%, 98%, or 99% identical to SEQ ID NOs. 98 and 99, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 99 and 98, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, or 90% identical to either SEQ ID NOs. 99 and 98,A fusion polypeptide that is 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 100 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, or 97% identical to either SEQ ID NOs. 100 or 101. A fusion polypeptide that is 98% or 99% identical to, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to, respectively, SEQ ID NOs. In some embodiments, the first and second fusion polypeptides are linked or connected by cleavable linkers selected from 2A cleavable peptides (e.g., foot-and-mouth disease virus (F2A), equine rhinitis A virus (E2A), porcine rhinitis virus-1 (P2A), and Thosea asigna virus (T2A)), furin recognition / cleavage sequences (e.g., RAKR (SEQ ID NO: 60), REKR (SEQ ID NO: 61), and RRKR (SEQ ID NO: 62)), and combinations, derivatives, or variants thereof. In some embodiments, the first and second fusion polypeptides contain or consist of the amino acid sequences of ATNFSLLKQAGDVEENPGP (SEQ ID NO: 63), APVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 64), RAKRAPVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 65), QCTNYALLKLAGDVESNPGP (SEQ ID NO: 66), or EGRGSLLTCGDVEENPGP (SEQ ID NO: 67), or ATNFSLLKQAGDVEENPGP (SEQ ID NO: 63),APVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 64), RAKRAPVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 65), QCTNYALLKLAGDVESNPGP (SEQ ID NO: 66), or EGRGSLLTCGDVEENPGP (SEQ ID NO: 67) are linked or connected by 2A cleavable peptides having an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least 99% identical to the amino acid sequence of SEQ ID NOs: 105-112, 200-209, 222-223, or SEQ ID NOs: 105-112, 200-209, 222-223, The complex fusion polypeptide contains or consists of an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of 209, 222, and 223. In some embodiments, the complex fusion polypeptide contains or consists of an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of 209, 222, and 223.

[0009] With regard to further embodiments of fusion polypeptides and complex fusion polypeptides, in some embodiments, the fusion polypeptide or complex fusion polypeptide further comprises an N-terminal signal peptide or leader sequence. In some embodiments, the signal peptide or leader sequence is derived from a source protein selected from serum proteins, cytokines, chemokines, chaperone proteins, invariant proteins, and proteins that direct proteins to lysosomal compartments. In some embodiments, the signal peptide or leader sequence is derived from a source protein selected from the group consisting of colony-stimulating factor 2 (CSF2, GM-CSF), tissue-type plasminogen activator (PLAT, t-PA), CC-motif chemokine ligand 7 (CCL7, MCP-3), CXC-motif chemokine ligand 10 (CXCL10, IP-10), catenin beta 1 (CTNNB1), CD74 (p33; DHLAG; HLADG; Ia-gamma, invariant chain), serum albumin (ALB), polyubiquitin B / C (UBB / UBC), calreticulin (CALR), vesicular stomatitis virus G protein (VSV-G), lysosome-associated membrane protein 1 (LAMP-1), and lysosome-associated membrane protein 2 (LAMP-2). In some embodiments, the signal peptide or leader sequence is selected from any one amino acid sequence of SEQ ID NOs: 115-126, or an amino acid sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 115-126. In some embodiments, the fusion polypeptide and / or complex fusion polypeptide are recombinantly produced or chemically synthesized. In some embodiments, the fusion polypeptide and / or complex fusion polypeptide can induce, promote, or stimulate an immune response in humans. In some embodiments, the fusion polypeptide and / or complex fusion polypeptide can induce, promote, or stimulate an immune response to HIV-1 in humans.In some embodiments, fusion polypeptides and / or complex fusion polypeptides can induce, promote, or stimulate the proliferation and / or activation of one or more cell types selected from monocyte-derived dendritic cells (DCs), CD8+ T cells, and CD4+ T cells.

[0010] Further provided are polynucleotides encoding one or more fusion polypeptides or complex fusion polypeptides, as described above and herein. In some embodiments, the polynucleotide comprises cDNA, mRNA, self-amplified RNA (SAM, saRNA), self-replicating RNA, or self-amplified replicon RNA (RepRNA). In some embodiments, the polynucleotide comprises a self-replicating or self-amplified alphavirus replicon. In some embodiments, the polynucleotide comprises one nucleic acid sequence of sequence numbers 130-167, 210-219, and 225-226, or a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to one of sequence numbers 130-167, 210-219, and 225-226. In some embodiments, the polynucleotide includes a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 95%, 96%, 97%, 98%, or 99% identical to any one of the nucleic acid sequences 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225, or 226. Further provided are expression cassettes comprising one or more regulatory sequences, for example, one or more polynucleotides described herein operably ligated to a promoter. In some embodiments, the polynucleotides are operably ligated to a constitutive promoter and are under its control. In some embodiments, the promoter is selected from the CMV promoter, the CAG promoter, and the EF1a promoter.

[0011] Lipoplexes, for example, lipid nanoparticles (LNPs), are further provided, which have, for example, one amino acid sequence of any one of SEQ ID NOs. 70-101, 105-112, 200-209, 222-223, and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs. The present invention comprises one or more polynucleotides described herein that encode one or more polypeptides, for example, one nucleic acid sequence of any one of SEQ ID NOs: 130-167, 210-219, and 225-226, or one or more polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 130-167, 210-219, and 225-226.In some embodiments, the lipoplex, for example, the lipid nanoparticles (LNPs), encode one or more polypeptides having an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of the amino acid sequences of SEQ ID NOs: 82-83, 85-87, 98-101, 209, and 222-223, as described herein. The polynucleotide comprises one or more nucleic acid sequences, for example, one of the nucleic acid sequences of sequence numbers 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225, and 226, or one of the nucleic acid sequences that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to one of the sequence numbers 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225, and 226.

[0012] A vector is further provided, comprising one or more polynucleotides and one or more expression cassettes. In some embodiments, the vector comprises or consists of one or more polynucleotides encoding one or more fusion polypeptides, each comprising the following polypeptide segments optionally linked or connected by one or more linkers from the N-terminus to the C-terminus: SEQ ID NOs. 6, 4, 16, and 26, and SEQ ID NOs. 7, 5, 27, and 17, SEQ ID NOs. 12, 24, 8, and 10, and SEQ ID NOs. 9, 25, 13, and 11, SEQ ID NOs. 14, 22, 18, 24, and 20, and SEQ ID NOs. 15, 25, 19, 23, and 2 1, SEQ ID NOs: 26, 16, 4, and 6, and SEQ ID NOs: 7, 27, 5, and 17, SEQ ID NOs: 8, 24, 12, and 10, and SEQ ID NOs: 13, 25, 9, and 11, SEQ ID NOs: 22, 24, 14, 18, and 20, and SEQ ID NOs: 25, 23, 15, 21, and 19, SEQ ID NOs: 20, 6, 4, 18, 16, and 26, and SEQ ID NOs: 7, 19, 5, 21, 27, and 17, SEQ ID NOs: 8, 24, 14, 12, 22, and 10, and SEQ ID NOs: 9, 13, 25, 23, 15, and 11, SEQ ID NOs: 18, 26, 20, 4, 6, and 16, and SEQ ID NOs. 7, 21, 17, 5, 27, and 19, SEQ ID NOs. 22, 24, 12, 14, 8, and 10, and SEQ ID NOs. 15, 25, 9, 23, 13, and 11, SEQ ID NOs. 24, 6, 4, 20, 18, and 32, and SEQ ID NOs. 8, 30, 14, 12, 26, and 10, SEQ ID NOs. 24, 6, 4, 20, 18, and 32, and SEQ ID NOs. 7, 21, 5, 25, 33, and 19, SEQ ID NOs. 24, 6, 4, 20, 18, and 32, and SEQ ID NOs. 8, 30, 14, 12, 26, and 10, SEQ ID NOs. 8, 30, 14, 12, 26, and 10, and sequence numbers 9, 13, 31, 27, 15, and 11, sequence numbers 6, 20, 4, 24, 32, and 18, and sequence numbers 8, 12, 30, 26, 14, and 10, sequence numbers 7, 21, 5, 25, 33, and 19, and sequence numbers 9, 13, 31, 27, 15, and 11, sequence numbers 20, 32, 24, 4, 6, and 18, and sequence numbers 26, 30, 12, 14, 8, and 10, sequence numbers 7, 25, 19, 5, 33, and 21, and sequence numbers 15, 31, 9, 27, 13, and 11, sequence numbers 24, 6, 16, and 18,and sequence numbers 26, 20, 10, and 28, sequence numbers 24, 6, 16, and 18, and sequence numbers 26, 10, 20, and 28, sequence numbers 24, 6, 16, and 18, and sequence numbers 7, 25, 17, and 19, sequence numbers 7, 19, 17, and 25, and sequence numbers 21, 27, 11, and 29, sequence numbers 24, 16, 6, and 18, and sequence numbers 27, 11, 21, and 29, sequence numbers 7, 25, 17, and 19, and sequence numbers 11, 27, 21, and 29, Sequence numbers 7, 25, 17, and 19, and sequence numbers 21, 27, 11, and 29, sequence numbers 22, 6, 20, and 28, and sequence numbers 23, 7, 21, and 29, sequence numbers 22, 20, 6, and 28, and sequence numbers 7, 21, 23, and 29, sequence numbers 26, 10, 20, and 28, and sequence numbers 21, 27, 11, and 29, sequence numbers 22, 6, 16, 20, 18, 28, 26, and 10, or sequence numbers 7, 21, 19, 17, 27, 25, 29, and 11. In some embodiments, the vector comprises one or more polynucleotides encoding one or more fusion polypeptides comprising, or comprising, an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to, any one of the amino acid sequences of 70-101, 105-112, 200-209, 222-223, or 227. In some embodiments, the vector contains an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 85%, 86%, 87%, 88%, 88%, 95%, 96%, 97%, 98%, or 99% identical to any one of the amino acid sequences 82–83, 85–87, 98–101, 209, and 222–223, or contains one or more polynucleotides encoding one or more fusion polypeptides composed of these sequences. In some embodiments, the vector contains,The following fusion polypeptides comprising one or more polynucleotides that optionally link or connect one or more linkers: fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 70 and 71, respectively; and fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 72 and 73, respectively Fusion polypeptides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 74 and 75, or fusion polypeptides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively, SEQ ID NOs. 76 and 77, or A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 76 or 77, respectively; SEQ ID NOs. 78 and 79; or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 78 and 79, respectively. A fusion polypeptide that is identical to SEQ ID NOs. 80 and 81, or any one of SEQ ID NOs. 80 and 81 by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively, a fusion polypeptide that is identical to SEQ ID NOs. 82 and 83, or any one of SEQ ID NOs. 82 and 83 by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, or 95%, respectively,Fusion polypeptides that are 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 84 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 86 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, or 89% identical to either SEQ ID NOs. 86 and 87, Fusion polypeptides that are 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 88 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 82 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, or 8% identical to one of SEQ ID NOs. 82 and 85. Fusion polypeptides identical to 4%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of Sequence ID No. 82 and 86, or fusion polypeptides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of Sequence ID No. 82 and 8 respectively Fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical, SEQ ID NOs. 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 83 or 87, respectively, SEQ ID NOs. 85 and 87,Or a fusion polypeptide identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of either SEQ ID NOs. 85 and 87, respectively; SEQ ID NOs. 88 and 87; or a fusion polypeptide identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of either SEQ ID NOs. 88 and 87, respectively. A fusion polypeptide that is identical to SEQ ID NOs. 84 and 88, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of either SEQ ID NOs. 85 and 89, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, or 95% of either SEQ ID NOs. 85 and 89, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, or 95% of either SEQ ID NOs. A fusion polypeptide that is identical to %, 96%, 97%, 98%, or 99% of SEQ ID NOs. 85 and 101, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of either SEQ ID NOs. 90 and 91, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, or 8 A fusion polypeptide that is identical to %, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 92 and 93, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 94 and 95, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, or a fusion polypeptide that is identical to at least 9A fusion polypeptide that is 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 96 and 97, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 8, Fusion polypeptides that are 9%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83% identical to fusion polypeptides that are at least 80%, 81%, 82%, 83% identical to fusion polypeptides that are at least 80%, 81%, 82%, 83% identical to fusion polypeptides that are at least 80%, 81%, 82%, 83% identical to fusion polypeptides that are at least 9%, 94%, 95%, 96%, 97%, 98%, or 99% identical to fusion A fusion polypeptide that is identical to %, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 220 and 221, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 98 and 100, or any A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of them, SEQ ID NOs. 99 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of them, A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either sequence numbers 98 and 99, or sequence numbers 100 and 101, or sequence numbers 100 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, or 96%,A fusion polypeptide that is 97%, 98%, or 99% identical. In some embodiments, the vector comprises one or more polynucleotides encoding the following first and second fusion polypeptides, which are optionally linked or connected by one or more linkers from the N-terminus to the C-terminus: SEQ ID NOs. 70 and 71, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 70 and 71, respectively. , fusion polypeptides identical to, at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of, fusion polypeptides identical to, at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, or 96 A fusion polypeptide that is identical to %, 97%, 98%, or 99% of Sequence ID No. 73 and 72, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of Sequence ID No. 74 and 75, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, or 8% of Sequence ID No. 74 and 75. A fusion polypeptide that is 9%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 75 and 74, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 76 and 77, or a fusion polypeptide that is at least 80%, 81%, or 99% identical to one of SEQ ID NOs. 76 and 77,Fusion polypeptides identical to 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of SEQ ID NOs. 77 and 76, or fusion polypeptides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of either SEQ ID NOs. 77 and 76, or SEQ ID NOs. 78 and 79, A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of the following: Sequence IDs 79 and 78, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of Sequence IDs 79 and 78, Sequence ID A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to 80 and 81, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or identical to either 80 and 80, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical fusion polypeptide, SEQ ID NOs. 82 and 83, or one of SEQ ID NOs. 82 and 83, and each fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 83 and 82, or one of SEQ ID NOs. 83 and 82, and each fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%,A fusion polypeptide that is 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 84 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 85 and 84, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, Fusion polypeptides that are 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 86 and 87, or each of SEQ ID NOs. 86 and 87, and each of them are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 87 and 86, or each of SEQ ID NOs. 87 and 86, and each of them are at least 80%, 81%, Fusion polypeptides that are 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 88 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 88 and 89, respectively, SEQ ID NOs. 89 and 88, or SEQ ID NOs. 89 and 88 A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either one of the following: SEQ ID NOs. 82 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either one of the following:A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 82 and 86, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, or 98% identical to either SEQ ID NOs. 82 and 86, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, or 98% identical to either SEQ ID NOs. Fusion polypeptides that are % or 99% identical to SEQ ID NOs. 86 and 82, or any one of SEQ ID NOs. 86 and 82, and each fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 82 and 88, or any one of SEQ ID NOs. 82 and 88, and each fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, Fusion polypeptides that are 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 88 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or 87% identical to either SEQ ID NOs. 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or 87% identical to either SEQ ID NOs. A fusion polypeptide that is identical to %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 87 and 83, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 85 and 87, or a fusion polypeptide that is identical to at least 80%, 81%,A fusion polypeptide that is 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical, with at least 80% of either SEQ ID NOs. 87 and 85, or with at least 80% of either SEQ ID NOs. 87 and 85. , fusion polypeptides identical to 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively, SEQ ID NOs. 88 and 87, or fusion polypeptides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively, SEQ ID NOs. 87 and 88, or SEQ ID NOs. 87 and A fusion polypeptide which is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 84 and 88, or a fusion polypeptide which is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 88 and 84. D, a fusion polypeptide identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of either SEQ ID NOs. 85 and 89, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, A fusion polypeptide that is 98% or 99% identical to SEQ ID NOs. 89 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 85 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, or 91% identical to either SEQ ID NOs. 85 and 101,A fusion polypeptide that is 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 101 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 90 and 91, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, or 84% identical to either SEQ ID NOs. 90 and 91, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, or 84% identical to either SEQ ID NOs. 90 and 91. A fusion polypeptide that is identical to %, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 91 and 90, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 92 and 93, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively, SEQ ID NOs. 92 and 93, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 96%, 98%, or 99%, respectively, SEQ ID NOs. 92 and 93, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively. Fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to each other, Sequence IDs 93 and 92, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to each other, Sequence IDs Fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to sequence numbers 94 and 95, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,A fusion polypeptide that is 98% or 99% identical to SEQ ID NOs. 96 and 97, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 97 and 96, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, A fusion polypeptide that is 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 94 and 96, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 96 and 94, or at least 80%, 81%, 82%, 83%, 84%, 85%, each identical to SEQ ID NOs. 96 and 94, Fusion polypeptides that are 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 95 and 97, or each of SEQ ID NOs. 95 and 97 are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 97 and 95, or each of SEQ ID NOs. 97 and 95 are at least Fusion polypeptides identical to 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 220 and 221, or fusion polypeptides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively, SEQ ID NOs. 221 and 220,Or a fusion polypeptide identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of either SEQ ID NOs. 221 and 220, respectively; SEQ ID NOs. 98 and 100, or a fusion polypeptide identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of either SEQ ID NOs. 98 and 100, respectively. A fusion polypeptide that is 9% identical to SEQ ID NOs. 100 and 98, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 99 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, or 93 A fusion polypeptide that is identical to %, 94%, 95%, 96%, 97%, 98%, or 99% of SEQ ID NOs. 101 and 99, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of either SEQ ID NOs. 98 and 99, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or 87 A fusion polypeptide that is identical to %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 99 and 98, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 100 and 101, or a fusion polypeptide that is identical to at least 80% of SEQ ID NOs. 100 and 101, or a fusion polypeptide that is identical to at least 80% of SEQ ID NOs. 100 and 101,A fusion polypeptide that is 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 101 and 100, or at least one of SEQ ID NOs. 101 and 100. In some embodiments, the vector comprises one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: SEQ ID NOs: 82 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs: 82 and 83, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: SEQ ID NOs: 84 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs: 84 and 85, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: SEQ ID NOs: 86 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs: 86 and 87, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: SEQ ID NOs: 86 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, or 99% identical to either SEQ ID NOs: 86 and 87, respectively.comprising one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 88 and 89, respectively. A fusion polypeptide. In some embodiments, the vector comprises one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: SEQ ID NOs. 82 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 82 and 85, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs: 82 and 86, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: SEQ ID NOs: 82 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs: 82 and 88, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: SEQ ID NOs: 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs: 83 and 87, respectively.In some embodiments, the vector comprises one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: SEQ ID NOs. 85 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 85 and 87, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: SEQ ID NOs. 88 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 88 and 87, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: SEQ ID NOs: 84 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs: 84 and 88, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: SEQ ID NOs. 85 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 85 and 89, respectively.In some embodiments, the vector comprises one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: SEQ ID NOs: 85 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs: 85 and 101, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: SEQ ID NOs: 90 and 91, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs: 90 and 91, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: SEQ ID NOs: 92 and 93, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs: 92 and 93, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs: 94 and 96, respectively.In some embodiments, the vector comprises one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs: 94 and 95, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: SEQ ID NOs. 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 95 and 97, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: SEQ ID NOs: 220 and 221, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs: 220 and 221, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs: 96 and 97, respectively.In some embodiments, the vector comprises one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: SEQ ID NOs. 98 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 98 and 99, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs: 98 and 100, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: SEQ ID NOs: 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs: 99 and 101, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: SEQ ID NOs: 100 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs: 100 and 101, respectively.In some embodiments, the vector comprises an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of the amino acid sequences of SEQ ID NOs: 105-112, 200-209, 222-223, and 227, or comprises a polynucleotide encoding a complex fusion polypeptide composed of these sequences. In some embodiments, the vector encodes a complex fusion polypeptide comprising, or consisting of, an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of the amino acid sequences of SEQ ID NOs. The fusion polypeptide contains polynucleotides. In some embodiments, the first and second fusion polypeptides do not contain Gag 54-146, Gag 370-500, Pol 1-55, Pol 118-128, Pol 321-366, Pol 432-541, Pol 607-682, Pol 709-746, Pol 828-839, Pol 921-931, Nef 1-63, Nef 100-116 and Nef 149-206, or any polypeptide segments corresponding to these fragments or subsequences, where the amino acid positions of Gag, Pol and Nef correspond to SEQ ID NOs: 1, 2 and 3, respectively. In some embodiments, the first and second fusion polypeptides do not contain a polypeptide segment having an amino acid sequence, or a fragment or subsequence thereof, of the amino acid sequences of SEQ ID NOs. 35-47, or any fragment or subsequence thereof, or an amino acid sequence, or a fragment or subsequence thereof, that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs. 35-47. In some embodiments, the vector includes, or includes, a polynucleotide composed of, a nucleic acid sequence which is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of the sequences which are 130–167, 210–219, or 225–226. In some embodiments, the vector contains a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 95%, 96%, 97%, 98%, or 99% identical to any one of sequence numbers 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225, or 226.or comprising polynucleotides comprising these. In some embodiments, the following first polynucleotides and second polynucleotides: polynucleotides identical to SEQ ID NOs. 130 and 132, or any one of SEQ ID NOs. 130 and 132 by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively; polynucleotides identical to SEQ ID NOs. 130 and 134, or any one of SEQ ID NOs. 130 and 134 by at least 80%, 81%, 82%, 83%, 84%, 8%. Polynucleotides identical to 5%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of SEQ ID NOs. 131 and 133, or polynucleotides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of either SEQ ID NOs. 131 and 135, or any of SEQ ID NOs. 131 and 135 Polynucleotides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of any one of them, SEQ ID NOs: 132 and 136, or polynucleotides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of either SEQ ID NOs: 132 and 136 20%Polynucleotides that are 94%, 95%, 96%, 97%, 98%, or 99% identical, SEQ ID NOs. 134 and 136, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 135 and 137, or at least 80%, 81%, 82%, 83%, 84%, 85%, 8% identical to SEQ ID NOs. 135 and 137, or at least 80%, 81%, 82%, 83%, 84%, 85%, 8% identical to SEQ ID NOs. 135 and 137, or at least 80%, 81%, 82%, 83%, 84%, 85%, 8% identical to SEQ ID NOs. 134 and 1364 and 136, or at least 80%, 81%, 82%, 83%, 84%, 85%, 8% identical to SEQ ID NOs. 134 and 136, or at least 80%, 81%, 82%, 83%, 84%, 8 Polynucleotides identical to 6%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of SEQ ID NOs. 138 and 141, or any one of SEQ ID NOs. 138 and 141, and each of SEQ ID NOs. 138 and 144, or any one of SEQ ID NOs. 138 and 144, and each Polynucleotides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, such as SEQ ID NOs. 139 and 142, or polynucleotides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, such as SEQ ID NOs. 139 and 145, or any one of SEQ ID NOs. 139 and 145, are identical by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% respectively to polynucleotides, SEQ ID NOs. 140 and 146, or any one of SEQ ID NOs. 140 and 146, are identical by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,Polynucleotides that are 98% or 99% identical to SEQ ID NOs. 142 and 148, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 143 and 149, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 8 Polynucleotides that are 9%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical, SEQ ID NOs. 145 and 148, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 150 and 152, or polynucleotides that are at least 80% identical to either SEQ ID NOs. 150 and 152, or polynucleotides that are at least 80% identical to either SEQ ID NOs. 150 and 152 Polynucleotides identical by %, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 150 and 155, or polynucleotides identical by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively, SEQ ID NOs. 151 and 155 3, or polynucleotides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of either SEQ ID NOs. 151 and 156, or polynucleotides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,Polynucleotides that are 98% or 99% identical to SEQ ID NOs. 152 and 158, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 153 and 159, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 8 Polynucleotides that are 9%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical, SEQ ID NOs. 154 and 157, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 155 and 158, or polynucleotides that are at least 80% identical to either SEQ ID NOs. 155 and 158, or polynucleotides that are at least 80% identical to either SEQ ID NOs. 154 and 1577, or polynucleotides that are at least 80% identical to either SEQ ID NOs. 154 and 157, or polynucleotides that are at least 80% identical to either SEQ ID NOs. 154 and Polynucleotides identical to %, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 156 and 159, or polynucleotides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively, SEQ ID NOs. 160 and 16 1, or a polynucleotide identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of either SEQ ID NOs. 162 and 163, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,Polynucleotides that are 98% or 99% identical, SEQ ID NOs. 164 and 165, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical, SEQ ID NOs. 166 and 167, and, polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 166 or 167, respectively; SEQ ID NOs. 210 and 211; or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% identical to either SEQ ID NOs. 210 and 211, respectively. Alternatively, polynucleotides that are 99% identical, SEQ ID NOs. 212 and 213, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 214 and 215, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, Polynucleotides that are 0%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical, SEQ ID NOs. 216 and 217, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 218 and 219, or polynucleotides that are at least 80%, 81% identical to either SEQ ID NOs. 218 and 219 Polynucleotides identical to %, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 218 and 226, or polynucleotides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively, or SEQ ID NOs. 225 and 226,or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NO: 225 or 226, respectively. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising SEQ ID NO: 130 or SEQ ID NO: 131, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% identical to either SEQ ID NO: 130 or SEQ ID NO: 131, respectively. (b) a polynucleotide that is 98% or 99% identical to (a) a second polynucleotide comprising SEQ ID NO: 134 or SEQ ID NO: 135, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 134 or SEQ ID NO: 135. In some embodiments, the vector comprises the following first and second polynucleotides: (a) the first polynucleotide comprising SEQ ID NO: 132 or SEQ ID NO: 133, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% of SEQ ID NO: 132 or (a) a polynucleotide that is 98% or 99% identical to (b) a second polynucleotide containing SEQ ID NO: 136 or SEQ ID NO: 137, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 136 or SEQ ID NO: 137. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide containing SEQ ID NO: 139, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, respectively identical to SEQ ID NO: 139.(b) polynucleotides that are 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to (a) a second polynucleotide containing SEQ ID NO: 145, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 145. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising SEQ ID NO: 142, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 142, and (b) a second polynucleotide comprising SEQ ID NO: 148, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 148. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising SEQ ID NO: 140, or a polynucleotide identical to SEQ ID NO: 140 by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%; and (b) a second polynucleotide comprising SEQ ID NO: 146, or a polynucleotide identical to SEQ ID NO: 146 by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%. In some embodiments, the vector comprises the following first and second polynucleotides: (a) the first polynucleotide comprising SEQ ID NO: 143, or SEQ ID NO: 143 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%,(b) a polynucleotide that is 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to (a) a second polynucleotide containing SEQ ID NO: 149, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 149. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising SEQ ID NO: 150, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 150, and (b) a second polynucleotide comprising SEQ ID NO: 152, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 152. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising SEQ ID NO: 151, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 151, and (b) a second polynucleotide comprising SEQ ID NO: 153, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 153. In some embodiments, the vector comprises the following first and second polynucleotides: (a) the first polynucleotide comprising SEQ ID NO: 154, or SEQ ID NO: 154 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%,(b) a polynucleotide that is 97%, 98%, or 99% identical to (a) a second polynucleotide containing SEQ ID NO: 157, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 157. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising SEQ ID NO: 155, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 155, and (b) a second polynucleotide comprising SEQ ID NO: 158, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 158. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising SEQ ID NO: 156, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 156; and (b) a second polynucleotide comprising SEQ ID NO: 159, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 159. In some embodiments, the vector comprises the following first and second polynucleotides: (a) the first polynucleotide comprising SEQ ID NO: 160, or SEQ ID NO: 160 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,(b) a polynucleotide that is 98% or 99% identical to (a) a second polynucleotide containing SEQ ID NO: 161, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 161, A polynucleotide. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising SEQ ID NO: 162, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 162, and (b) a second polynucleotide comprising SEQ ID NO: 163, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 163. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising SEQ ID NO: 164, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 164, and (b) a second polynucleotide comprising SEQ ID NO: 165, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 165. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising SEQ ID NO: 166, or a polynucleotide identical to SEQ ID NO: 166 by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively; and (b) a second polynucleotide comprising SEQ ID NO: 167, or a polynucleotide identical to SEQ ID NO: 167 by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%.In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising SEQ ID NO: 210, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 210; and (b) a second polynucleotide comprising SEQ ID NO: 211, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 211. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising SEQ ID NO: 212, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 212; and (b) a second polynucleotide comprising SEQ ID NO: 213, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 213. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising SEQ ID NO: 214, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 214; and (b) a second polynucleotide comprising SEQ ID NO: 215, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 215.In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising SEQ ID NO: 216, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 216; and (b) a second polynucleotide comprising SEQ ID NO: 217, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 217. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising SEQ ID NO: 218, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 218; and (b) a second polynucleotide comprising SEQ ID NO: 219, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 219. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising SEQ ID NO: 218, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 218; and (b) a second polynucleotide comprising SEQ ID NO: 226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 226.In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising SEQ ID NO: 225, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 225; and (b) a second polynucleotide comprising SEQ ID NO: 226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 226. In some embodiments, the first polynucleotide encoding the first fusion polypeptide and the second polynucleotide encoding the second fusion polypeptide are located in a single open reading frame. In some embodiments, the first polynucleotide encoding the first fusion polypeptide is located in a first open reading frame, and the second polynucleotide encoding the second fusion polypeptide is located in a second open reading frame. In some embodiments, the first polynucleotide encoding the first fusion polypeptide and the second polynucleotide encoding the second fusion polypeptide are located in a single expression cassette. In some embodiments, the first polynucleotide encoding the first fusion polypeptide is located in a first expression cassette, and the second polynucleotide encoding the second fusion polypeptide is located in a second expression cassette. In some embodiments, the vector is a plasmid vector, a bacterial vector, or a viral vector. In some embodiments, the vector is a viral vector. In some embodiments, the viral vector is a DNA virus or an RNA virus. In some embodiments, the viral vector is replication-deficient, replication-deleted, replication-attenuated, or replication-capable.In some embodiments, the viral vector is derived from a virus selected from adenoviruses, adeno-associated viruses, arenaviruses, alphaviruses, poxviruses, cytomegaloviruses, rhabdoviruses, vesicular stomatitis viruses, flaviviruses, marabaviruses, and vacciniaviruses. In some embodiments, the viral vector is derived from a virus belonging to a taxonomic family selected from the adenoviridae, arenaviridae, herpesviridae (e.g., cytomegalovirus), poxviridae (e.g., vaccinia virus, e.g., modified vaccinia ankara (MVA)), flaviviridae (e.g., yellow fever virus), rhabdoviridae (e.g., becyclovirus, e.g., marababecyclovirus), and togaviridae (e.g., alphavirus, e.g., Venezuelan encephalitis virus). In some embodiments, the viral vector is an arenavirus vector selected from lymphocytic choriomeningitis mammalenavirus (LCMV), Kali mammalenavirus (also known as pichin de mammalenavirus or pichin de arenavirus), guanalitovirus (GTOV), Junin virus (JUNV), Lassa virus (LASV), Lujo virus (LUJV), Macpo virus (MACV), Sabia virus (SABV), and Whitewater Arroyo virus (WWAV). In some embodiments, the viral vector is an arenavirus vector selected from lymphocytic choriomeningitis mammalenavirus (LCMV) or Kali mammalenavirus (also known as pichin de mammalenavirus or pichin de arenavirus). In some embodiments, the arenavirus vector includes a 2-segmented genome. In some embodiments, the arenavirus vector includes a 3-segmented genome. In some embodiments, the viral vector is a human adenovirus or a monkey adenovirus (e.g., chimpanzee adenovirus, gorilla adenovirus, or rhesus monkey adenovirus).In some embodiments, the viral vector may be adenovirus serotype 5 (Ad5), adenovirus serotype 26 (Ad26), adenovirus serotype 34 (Ad34), adenovirus serotype 35 (Ad35), adenovirus serotype 48 (Ad48), chimpanzee adenovirus (e.g., ChAd3 (AdC3), ChAd5 (AdC5), ChAd6 (AdC6), ChAd7 (AdC7), ChAd8 (AdC8), ChAd9 (Ad C9), ChAd10(AdC10), ChAd11(AdC11), ChAd17(AdC17), ChAd16(AdC16), ChAd19(AdC19), ChAd20(AdC20), ChAd22(AdC22 ), ChAd24(AdC24), ChAdY25, ChAd26(AdC26), ChAd28(AdC28), ChAd30(AdC30), ChAd31(AdC31), ChAd37(AdC37), ChAd38. (AdC38), ChAd43(AdC43), ChAd44(AdC44), ChAd55(AdC55), ChAd63(AdC63), ChAdV63, ChAd68(AdC68), ChAd73(A dC73), ChAd82(AdC82), ChAd83(AdC83), ChAd143(AdC143), ChAd144(AdC144), ChAd145(AdC145), ChAd147(AdC1 47)) Adenovirus vectors selected from gorilla adenoviruses (e.g., GC44, GC45, GC46) and rhesus macaque adenoviruses (e.g., RhAd51, RhAd52, RhAd53, RhAd54, RhAd55, RhAd56, RhAd57, RhAd58, RhAd59, RhAd60, RhAd61, RhAd62, RhAd63, RhAd64, RhAd65, RhAd66).

[0013] Further provided herein are host cells comprising one or more polynucleotides, one or more expression cassettes, or one or more vectors. In some embodiments, one or more polynucleotides are not integrated into the host cell genome and are, for example, episomal. In some embodiments, one or more polynucleotides are integrated into the host cell genome. In some embodiments, the host cell is a mammalian cell, for example, a human cell. In various embodiments, the host cell may be in vitro or in vivo.

[0014] Further immunogenic compositions are provided. In various embodiments, the immunogenic composition comprises one or more fusion polypeptides or complex fusion polypeptides, one or more polynucleotides, or one or more vectors as described herein, and a pharmaceutically acceptable carrier. In some embodiments, the immunogenic composition comprises two or more fusion polypeptides or complex fusion polypeptides, two or more polynucleotides, or two or more vectors as described herein. In some embodiments, one or more polynucleotides are DNA, cDNA, mRNA, or self-replicating RNA. In some embodiments, the immunogenic composition comprises one or more vectors comprising a first fusion polypeptide and a second fusion polypeptide, or one or more polynucleotides encoding the first and second fusion polypeptides, wherein the first and second polypeptides comprise the following polypeptide segments optionally linked or connected by one or more linkers from the N-terminus to the C-terminus: SEQ ID NOs: 6, 4, 16, and 26, and SEQ ID NOs: 7, 5, 27, and 17, SEQ ID NOs: 12, 24, 8, and 10, and SEQ ID NOs: 9, 25, 13, and 11, SEQ ID NOs: 14, 22, 18, 24, and 20, and SEQ ID NOs: 15, 25, 19, 23, and 21, SEQ ID NOs: 26, 16, 4, and 6, and SEQ ID NOs: 7, 27, 5, and 17, SEQ ID NOs: 8, 24, 12, and 10, and SEQ ID NOs: 13, 25, 9, and 11, SEQ ID NOs: 22, 24, 14, 18, and 20, and sequence numbers 25, 23, 15, 21, and 19, sequence numbers 20, 6, 4, 18, 16, and 26, and sequence numbers 7, 19, 5, 21, 27, and 17, sequence numbers 8, 24, 14, 12, 22, and 10, and sequence numbers 9, 13, 25, 23, 15, and 11, sequence numbers 18, 26, 20, 4, 6, and 16, and sequence numbers 7, 21, 17, 5, 27, and 19, sequence number 22, 24, 12, 14, 8, and 10, and sequence numbers 15, 25, 9, 23, 13, and 11, sequence numbers 24, 6, 4, 20, 18, and 32, and sequence numbers 8, 30, 14, 12, 26, and 10, sequence numbers 24, 6, 4, 20, 18, and 32, and sequence numbers 7, 21, 5, 25, 33, and 19, sequence numbers 24, 6, 4, 20, 18, and 32, and sequence numbers 8, 30, 14, 12, 26, and 10,Sequence numbers 8, 30, 14, 12, 26, and 10, as well as sequence numbers 9, 13, 31, 27, 15, and 11, sequence numbers 6, 20, 4, 24, 32, and 18, as well as sequence numbers 8, 12, 30, 26, 14, and 10, sequence numbers 7, 21, 5, 25, 33, and 19, as well as sequence numbers 9, 13, 31, 27, 15, and 11, sequence numbers 20, 32, 24, 4, 6, and 18, and to sequence numbers 26, 30, 12, 14, 8, and 10, sequence numbers 7, 25, 19, 5, 33, and 21, and sequence numbers 15, 31, 9, 27, 13, and 11, sequence numbers 24, 6, 16, and 18, and sequence numbers 26, 20, 10, and 28, sequence numbers 24, 6, 16, and 18, and sequence numbers 26, 10, 20, and 28, sequence numbers 24, 6, 16, and 18, and sequence numbers Numbers 7, 25, 17, and 19, Sequence numbers 7, 19, 17, and 25, and Sequence numbers 21, 27, 11, and 29, Sequence numbers 24, 16, 6, and 18, and Sequence numbers 27, 11, 21, and 29, Sequence numbers 7, 25, 17, and 19, and Sequence numbers 11, 27, 21, and 29, Sequence numbers 7, 25, 17, and 19, and Sequence numbers 21, 27, 11, and 29, Sequence number Sequence numbers 22, 6, 20, and 28, and sequence numbers 23, 7, 21, and 29, sequence numbers 22, 20, 6, and 28, and sequence numbers 7, 21, 23, and 29, sequence numbers 26, 10, 20, and 28, and sequence numbers 21, 27, 11, and 29, sequence numbers 22, 6, 16, 20, 18, 28, 26, and 10, or sequence numbers 7, 21, 19, 17, 27, 25, 29, and 11. In some embodiments, the immunogenic composition comprises one or more fusion polypeptides, or a vector comprising one or more polynucleotides encoding one or more fusion polypeptides comprising one of the amino acid sequences of SEQ ID NOs. 70-101, 105-112, 200-209, 222-223, and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to one of the amino acid sequences of SEQ ID NOs.The immunogenic composition comprises one or more fusion polypeptides, or a vector comprising one or more polynucleotides encoding one or more fusion polypeptides, or one of the amino acid sequences of SEQ ID NOs. 82-83, 85-87, 98-101, 209, and 222-223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to one of the SEQ ID NOs. In some embodiments, the immunogenic composition comprises one or more polynucleotides, or one or more vectors or one or more lipoplexes (e.g., LNPs), each comprising: a first fusion polypeptide and a second fusion polypeptide, each optionally linked or connected by one or more linkers; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 70 and 71, each comprising: a fusion polypeptide; and either SEQ ID NOs. 72 and 73, each comprising either SEQ ID NOs. 72 and 73. A fusion polypeptide which is identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of each, SEQ ID NOs. 74 and 75, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87% of either SEQ ID NOs. 74 or 75, A fusion polypeptide that is 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 76 and 77, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,Fusion polypeptides that are 98% or 99% identical to SEQ ID NOs. 78 and 79, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 80 and 81, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, or 91 A fusion polypeptide that is identical to 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of SEQ ID NOs. 82 and 83, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of either SEQ ID NOs. 84 and 85, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, 84%, or 8% of either SEQ ID NOs. 84 and 85. Fusion polypeptides that are 5%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 86 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 88 and 89 or 99% identical to either SEQ ID NOs. 88 and 89 Fusion polypeptides, SEQ ID NOs. 82 and 85, which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical, respectively, or fusion polypeptides, SEQ ID NOs. 82 and 86, which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 82 and 85, respectively.Or a fusion polypeptide identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of either SEQ ID NOs. 82 and 88, or identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of either SEQ ID NOs. A fusion polypeptide that is identical to SEQ ID NOs. 83 and 87, or one of SEQ ID NOs. 83 and 87 by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively, a fusion polypeptide that is identical to SEQ ID NOs. 85 and 87, or one of SEQ ID NOs. 85 and 87 by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, or 95% respectively. A fusion polypeptide that is identical to %, 96%, 97%, 98%, or 99% of Sequence ID No. 88 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of Sequence ID No. 84 and 88, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, or 89% of Sequence ID No. 84 and 88, A fusion polypeptide that is 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 85 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 85 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83% identical to either SEQ ID NOs. 85 and 101,A fusion polypeptide that is 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 90 and 91, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, respectively identical to either SEQ ID NOs. 90 or 91. A fusion polypeptide that is identical to %, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of SEQ ID NOs. 92 and 93, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of either SEQ ID NOs. 94 and 95, or a fusion polypeptide that is identical to at least 80%, 81%, or 82% of either SEQ ID NOs. 94 and 95 , fusion polypeptides identical to 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 96 and 97, or fusion polypeptides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 94 and 96, or either SEQ ID NOs. 94 and 96 A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to one of the fusion polypeptides, SEQ ID NOs. 95 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to one of the fusion polypeptides, SEQ ID NOs. 2 Fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to 20 and 221, or any one of sequence numbers 220 and 221, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, or 97% identical to sequence numbers 98 and 100, respectively;A fusion polypeptide that is 98% or 99% identical to SEQ ID NOs. 99 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 98 and 99, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, or 84% identical to either SEQ ID NOs. 98 and 99. A fusion polypeptide that is identical to %, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively, or a fusion polypeptide that is identical to SEQ ID NOs. 100 and 101, or to either SEQ ID NOs. 100 and 101, by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively. In some embodiments, the immunogenic composition comprises one or more polynucleotides, or one or more vectors or one or more lipoplexes (e.g., LNPs), each comprising one or more polynucleotides encoding the following first and second fusion polypeptides, which are optionally linked or connected from the N-terminus to the C-terminus by one or more linkers: SEQ ID NOs. 70 and 71, or one of SEQ ID NOs. 70 and 71, each comprising at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 9%. Fusion polypeptides that are 1%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 71 and 70, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 72 and 73, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, respectively.Fusion polypeptides that are 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 73 and 72, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 74 and 75, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or 8% identical to Fusion polypeptides that are 7%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 75 and 74, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 76 and 77, or fusion polypeptides that are at least 80%, 81% identical to Fusion polypeptides identical to %, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 77 and 76, or fusion polypeptides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 78 and 79, or SEQ ID NOs. 78 and 79 A fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of any one of the above, SEQ ID NOs. 79 and 78, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of any one of SEQ ID NOs. 79 and 78,A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 81 and 80, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% identical to either SEQ ID NOs. 81 and 80, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% identical to either SEQ ID NOs. Fusion polypeptides that are % or 99% identical to SEQ ID NOs. 82 and 83, or any one of SEQ ID NOs. 82 and 83, and each fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 83 and 82, or any one of SEQ ID NOs. 83 and 82, and each fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, Fusion polypeptides that are 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 84 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 85 and 84, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or 87% identical to fusion polypeptides that are at least7% identical to fusion polypeptides that are at least 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. A fusion polypeptide that is identical to %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 86 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 87 and 86, or at least 80%, 81%,Fusion polypeptides that are 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical, SEQ ID NOs. 88 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 88 and 89, or SEQ ID NOs. 89 and 88 A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of the following: SEQ ID NOs. 82 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of the following: SEQ ID NOs. A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to 85 and 82, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or identical to either 85 and 82, or identical to either 82 and 86, or identical to either 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical fusion polypeptide, SEQ ID NOs. 86 and 82, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical fusion polypeptide, SEQ ID NOs. 82 and 88, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%,A fusion polypeptide that is 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 88 and 82, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, or 92% identical to either SEQ ID NOs. 88 or 82, respectively. A fusion polypeptide that is identical to %, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of SEQ ID NOs. 83 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of either SEQ ID NOs. 87 and 83, or at least 80%, 81%, 82%, 83%, 84%, 85%, or 86% of either SEQ ID NOs. 87 and 83, or at least 80%, 81%, 82%, 83%, 84%, 85%, or 86% of either SEQ ID NOs. , fusion polypeptides identical to 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of SEQ ID NOs. 85 and 87, or fusion polypeptides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of either SEQ ID NOs. 87 and 85, or fusion polypeptides identical to at least 80%, 8 Fusion polypeptides identical to 1%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of Sequence ID No. 88 and 87, or fusion polypeptides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of Sequence ID No. 88 and 88, or Sequence ID No. 87 and 8 A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of the eight, SEQ ID NOs. 84 and 88, or aFusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 85 and 89, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% identical to either SEQ ID NOs. 85 and 89, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% identical to either SEQ ID NOs. Fusion polypeptides that are % or 99% identical to SEQ ID NOs. 89 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 85 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, or 92 A fusion polypeptide that is identical to %, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of SEQ ID NOs. 101 and 85, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of either SEQ ID NOs. 90 and 91, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, 84%, 85%, or 86% of either SEQ ID NOs. 90 and 91, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, 84%, 85%, or 86% of either SEQ ID NOs. 90 and 91. A fusion polypeptide that is identical to %, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 91 and 90, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 92 and 93, or a fusion polypeptide that is identical to at least 80% to one of SEQ ID NOs. 92 and 93,Fusion polypeptides identical to 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively, SEQ ID NOs. 93 and 92, or fusion polypeptides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively, SEQ ID NOs. 94 and 95, or SEQ ID NOs. 94 and 95 A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of the five, SEQ ID NOs. 95 and 94, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of the five, Fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 97 and 96, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% identical to either SEQ ID NOs. 97 and 96, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% identical to either SEQ ID NOs. A fusion polypeptide that is % or 99% identical to SEQ ID NOs. 94 and 96, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 96 and 94, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%,Fusion polypeptides that are 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 97 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, or 86% identical to fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, or 86% identical to fusion polypeptides that are at least 86% identical to fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, or 86% identical to fusion polypeptides that are at least 96% identical to fusion polypeptides that are at least 94%, 95%, 96%, 97%, 98%, or 94%, 97%, 95%, 96%, 97 A fusion polypeptide that is identical to %, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of SEQ ID NOs. 220 and 221, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of either SEQ ID NOs. 221 and 220 either SEQ ID NOs. 221 and 220, or a fusion polypeptide that is identical to either SEQ ID NOs. 221 and 220, or a fusion polypeptide that is identical to either SEQ ID NOs. 221 and 220, or a fusion polypeptide that is identical to either SEQ ID NOs. 221 and 220, or a fusion polypeptide that is identical to either SEQ ID NOs. 221 and 220, or a fusion polypeptide that is identical to either SEQ ID NOs. 221 and 220, or a fusion polypeptide that is identical to either SEQ ID NOs. 221 and 220, or a fusion polypeptide that is identical to either SEQ ID NOs. 221 and 220, or a Fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to each other, SEQ ID NOs. 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to each other, SEQ ID NOs. 1 Fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either 00 and 98, or any one of SEQ ID NOs. 99 and 101, or any one of SEQ ID NOs. 99 and 101, are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,Fusion polypeptides that are 98% or 99% identical, SEQ ID NOs. 101 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 101 or 99, SEQ ID NOs. 98 and 99, or SEQ ID NOs. A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either 98 or 99, respectively; SEQ ID NOs. 99 and 98; or at least 80%, 81%, 82%, 83%, 84% identical to either 99 or 98, respectively. A fusion polypeptide that is 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 100 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, or 94% identical to either SEQ ID NOs. 100 or 101. A fusion polypeptide that is 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 101 and 100, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. In some embodiments, the immunogenic composition comprises first and second polynucleotides, first and second viral vectors, or first and second lipoplexes (e.g., LNPs), each comprising one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: (a) the first and second fusion polypeptides comprising SEQ ID NOs. 82 and 83, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, each comprising at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%,(b) a first polynucleotide or a first viral vector or a first lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide that is 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical, (b) a first fusion polypeptide comprising SEQ ID NOs. 86 and 87, A second polynucleotide, a second viral vector, or a second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 86 and 87, respectively. In some embodiments, the immunogenic composition comprises a first and second polynucleotide or a first and second viral vector or a first and second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: (a) a first and second fusion polypeptide comprising SEQ ID NOs. 84 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 84 or 85, respectively. (b) a first polynucleotide or a first viral vector or a first lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide which is (a) a first fusion polypeptide comprising SEQ ID NOs. 88 and 89 and a second fusion polypeptide, or a second polynucleotide or a second viral vector or a second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide which is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 88 or 89, respectively.In some embodiments, the immunogenic composition comprises a first and second polynucleotide or a first and second viral vector or a first and second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: (a) a first and second fusion polypeptide comprising SEQ ID NOs. 82 and 86, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 82 or 86, respectively. (b) a first polynucleotide or a first viral vector or a first lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide which is (a) a first fusion polypeptide comprising SEQ ID NOs. 83 and 87 and a second fusion polypeptide, or a second polynucleotide or a second viral vector or a second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide which is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs. 83 and 87, respectively.In some embodiments, the immunogenic composition comprises first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: (a) the first and second fusion polypeptides comprising SEQ ID NOs. 82 and 85, or the fusion polynucleotides which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. (b) a first polynucleotide or a first viral vector or a first lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a tide; (b) a first fusion polypeptide comprising SEQ ID NOs. 88 and 87 and a second fusion polypeptide, or a second polynucleotide or a second viral vector or a second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 88 or 87, respectively.In some embodiments, the immunogenic composition comprises a first and second viral vector or a first and second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: (a) a first and second fusion polypeptide comprising SEQ ID NOs. 82 and 88, or a fusion polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. (b) a first polynucleotide or a first viral vector or a first lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a tide; (b) a first fusion polypeptide comprising SEQ ID NOs. 85 and 87 and a second fusion polypeptide, or a second polynucleotide or a second viral vector or a second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs. 85 and 87, respectively.In some embodiments, the immunogenic composition comprises a first and second polynucleotide or a first and second viral vector or a first and second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: (a) a first and second fusion polypeptide comprising SEQ ID NOs. 84 and 88, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 84 or 88, respectively. (b) a first polynucleotide or a first viral vector or a first lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide which is (a) a first fusion polypeptide comprising SEQ ID NOs. 85 and 89 and a second fusion polypeptide, or a second polynucleotide or a second viral vector or a second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide which is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 85 or 89, respectively.In some embodiments, the immunogenic composition comprises a first and second polynucleotide or a first and second viral vector or a first and second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: (a) the first and second fusion polypeptides comprising SEQ ID NOs. 98 and 100, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 98 or 100, respectively. (b) a first polynucleotide or a first viral vector or a first lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide which is (a) a first fusion polypeptide comprising SEQ ID NOs. 85 and 101 and a second fusion polypeptide, or a second polynucleotide or a second viral vector or a second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide which is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 85 and 101, respectively. In some embodiments, the immunogenic composition comprises a viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: SEQ ID NOs. 90 and 91, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 90 and 91, respectively.In some embodiments, the immunogenic composition comprises a viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: SEQ ID NOs. 92 and 93, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 92 and 93, respectively. In some embodiments, the composition comprises first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: (a) a first and second fusion polypeptide comprising SEQ ID NOs. 94 and 95, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 94 or 95, respectively. (b) a first polynucleotide or a first viral vector or a first lipoplex (e.g., LNP) comprising one or more polynucleotides encoding (a) a first fusion polypeptide comprising SEQ ID NOs. 96 and 97 and a second fusion polypeptide, or a second polynucleotide or a second viral vector or a second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide which is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs. 96 and 97, respectively. In some embodiments, the immunogenic compositions are optionally linked or connected by one or more linkers. The first and second polynucleotides or the first and second viral vectors or the first and second lipoplex (e.g., LNP) each comprising one or more polynucleotides encoding the following first and second fusion polypeptides and second fusion polypeptides: (a) the first and second fusion polypeptides comprising SEQ ID NOs. 94 and 96, or one or more polynucleotides encoding fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 94 or 96, respectively. (b) a first polynucleotide or a first viral vector or a first lipoplex (e.g., LNP) comprising a nucleotide, (b) a first fusion polypeptide comprising SEQ ID NOs. 95 and 97 and a second fusion polypeptide, or a second polynucleotide or a second viral vector or a second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide which is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs. 95 and 97, respectively.In some embodiments, the immunogenic composition comprises a first and second polynucleotide or a first and second viral vector or a first and second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: (a) a first and second fusion polypeptide comprising SEQ ID NOs. 220 and 221, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% (b) a first polynucleotide or a first viral vector or a first lipoplex (e.g., LNP) comprising one or more polynucleotides encoding identical fusion polypeptides, (b) a first fusion polypeptide comprising SEQ ID NOs. 95 and 97 and a second fusion polypeptide, or a second polynucleotide or a second viral vector or a second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 95 or 97, respectively.In some embodiments, the immunogenic composition comprises a first and second polynucleotide or a first and second viral vector or a first and second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: (a) the first and second fusion polypeptides comprising SEQ ID NOs. 98 and 100, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 98 or 100, respectively. (b) a first polynucleotide or a first viral vector or a first lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide which is (a) a first fusion polypeptide comprising SEQ ID NOs. 99 and 101 and a second fusion polypeptide, or a second polynucleotide or a second viral vector or a second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide which is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 99 or 101, respectively. In some embodiments, the immunogenic composition comprises a viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, each comprising a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 82 and 85, or any one of SEQ ID NOs. 82 and 85, respectively, linked or connected by one or more linkers.In some embodiments, the immunogenic composition comprises a viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, each comprising a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 82 and 88, or any one of SEQ ID NOs. 82 and 88, respectively, linked or connected by one or more linkers. In some embodiments, the immunogenic composition comprises a viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, each comprising a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 85 and 87, or any one of SEQ ID NOs. 85 and 87, respectively, linked or connected by one or more linkers. In some embodiments, the immunogenic composition comprises a viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, each comprising a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 87 and 88, or any one of SEQ ID NOs. 87 and 88, respectively, linked or connected by one or more linkers.In some embodiments, the immunogenic composition comprises a viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, each comprising a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 94 and 95, or any one of SEQ ID NOs. 94 and 95, respectively, linked or connected by one or more linkers. In some embodiments, the immunogenic composition comprises a viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, each comprising a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 96 and 97, or any one of SEQ ID NOs. 96 and 97, respectively, linked or connected by one or more linkers. In some embodiments, the immunogenic composition comprises a viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, each comprising a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 98 and 99, or any one of SEQ ID NOs. 98 and 99, respectively, linked or connected by one or more linkers.In some embodiments, the immunogenic composition comprises a viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, each comprising a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 100 and 101, or any one of SEQ ID NOs. 100 and 101, respectively, linked or connected by one or more linkers. In some embodiments, the immunogenic composition comprises a first viral vector or lipoplex (e.g., a first polynucleotide encoding a polypeptide comprising a first polypeptide containing SEQ ID NO: 200, or a first polynucleotide encoding a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 200) The invention comprises a second viral vector or lipoplex (e.g., LNP) and a second polynucleotide encoding a polypeptide containing SEQ ID NO: 201, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 201.In some embodiments, the immunogenic composition comprises a first viral vector or lipoplex (e.g., a first polynucleotide encoding a polypeptide comprising a first polypeptide containing SEQ ID NO: 202, or a first polynucleotide encoding a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 202. The invention comprises a second viral vector or lipoplex (e.g., LNP) and a second polynucleotide encoding a polypeptide containing SEQ ID NO: 203, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 203. In some embodiments, the immunogenic composition comprises a first viral vector or lipopy containing a first polynucleotide encoding a polypeptide comprising a first polypeptide containing SEQ ID NO: 203, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 203. A second viral vector or lipoplex (e.g., REX (e.g., LNP)) and a second polynucleotide encoding a polypeptide containing SEQ ID NO: 204, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 204. For example, LNP) and a first viral vector or lipoplex (e.g., a first polynucleotide encoding a polypeptide comprising a first polypeptide comprising SEQ ID NO: 105, or a first polynucleotide encoding a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 105. The invention comprises a second viral vector or lipoplex (e.g., LNP) and a second polynucleotide encoding a polypeptide containing SEQ ID NO: 107, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 107. In some embodiments, the immunogenic composition comprises a first viral vector or lipoplex (e.g., a first polynucleotide encoding a polypeptide comprising a first polypeptide comprising SEQ ID NO: 206, or a first polynucleotide encoding a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 206. The invention comprises a second viral vector or lipoplex (e.g., LNP) and a second polynucleotide encoding a polypeptide containing SEQ ID NO: 207, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 207. In some embodiments, the immunogenic composition comprises a first viral vector or lipoplex (e.g., LNP) comprising a first polynucleotide encoding a polypeptide containing SEQ ID NO: 208, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 208, and a second,A second viral vector or lipoplex (e.g., LNP) comprising a polypeptide containing SEQ ID NO: 209 or SEQ ID NO: 227, or a second polynucleotide encoding a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 209 or SEQ ID NO: 227. In some embodiments, the immunogenic composition comprises a first viral vector or lipoplex (e.g., LNP) comprising a first polynucleotide encoding a polypeptide comprising a first sequence number 222, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to sequence number 222, and a second A second viral vector or lipoplex (e.g., LNP) comprising a polypeptide containing SEQ ID NO: 209 or SEQ ID NO: 227, or a second polynucleotide encoding a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 209 or SEQ ID NO: 227. In some embodiments, the immunogenic composition comprises a first viral vector or lipoplex comprising a first polynucleotide encoding a polypeptide comprising SEQ ID NO: 222, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 222. A second viral vector or lipoplex (e.g., LNP) comprising a second polynucleotide encoding a polypeptide containing SEQ ID NO: 223, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 223,This includes. In some embodiments, the immunogenic composition includes, or includes, a nucleic acid sequence which is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of the sequences which include 130-167, 210-219, and 225-226, or a polynucleotide which comprises these. In some embodiments, the immunogenic composition comprises or comprises a polynucleotide comprising any one nucleic acid sequence of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225, and 226, or a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225, and 226. In some embodiments, the immunogenic composition comprises the following first polynucleotide and second polynucleotide, or one or more vectors comprising the following first polynucleotide and second polynucleotide: SEQ ID NOs. 130 and 132, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 130 and 132, respectively. Polynucleotides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of each of sequence numbers 131 and 133, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%,Polynucleotides that are 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 131 and 135, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 132 and 136, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or 87% identical to SEQ ID NOs. 132 and 136. Polynucleotides that are 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 133 and 135, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 133 and 137 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 133 and 137, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 133 and 137, or at least 80%, 81%, 82%, 83%, 84%, 85%, 95%, 96%, 97%, 98%, or 99% identical Polynucleotides identical to both SEQ ID NOs. 134 and 136 by 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively, SEQ ID NOs. 134 and 136, or polynucleotides identical to either SEQ ID NOs. 134 or 136 by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively, SEQ ID NOs. 135 and Polynucleotides identical to 137, or any one of SEQ ID NOs. 135 and 137 by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively; SEQ ID NOs. 138 and 141, or any one of SEQ ID NOs. 138 and 141, by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, respectively.Polynucleotides that are 98% or 99% identical to SEQ ID NOs. 138 and 144, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 139 and 142, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 8 Polynucleotides that are 9%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical, SEQ ID NOs. 139 and 145, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 140 and 146, or polynucleotides that are at least 80% identical to either SEQ ID NOs. 140 and 146 Polynucleotides identical by %, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 142 and 148, or polynucleotides identical by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively, SEQ ID NOs. 143 and 148 9, or polynucleotides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of either SEQ ID NOs. 145 and 148, or polynucleotides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,Polynucleotides that are 98% or 99% identical, SEQ ID NOs. 150 and 152, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 150 or 152, each with a sequence number, Polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to sequence numbers 150 and 155, or any one of sequence numbers 150 and 155, respectively; polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, or 96% identical to sequence numbers 151 and 153, or any one of sequence numbers 151 and 153, respectively. Polynucleotides that are identical by %, 97%, 98%, or 99%, SEQ ID NOs. 151 and 156, or polynucleotides that are identical by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 152 and 158, or polynucleotides that are identical by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, or 88% respectively to one of Polynucleotides that are identical by %, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, to SEQ ID NOs. 153 and 159, or polynucleotides that are identical by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% to either SEQ ID NOs. 154 and 157, or polynucleotides that are identical by at least 8% to either SEQ ID NOs. 154 and 157, or polynucleotides that are identical by at least 8% to either SEQ ID NOs. 154 and 157 Polynucleotides identical to 0%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 155 and 158, or polynucleotides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively, SEQ ID NOs. 156 and 159,Or polynucleotides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of either SEQ ID NOs: 156 and 159, respectively; SEQ ID NOs: 160 and 161, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% of either SEQ ID NOs: 160 and 161, respectively. Polynucleotides that are % or 99% identical, SEQ ID NOs. 162 and 163, or any one of SEQ ID NOs. 162 and 163, and each of these polynucleotides are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical, SEQ ID NOs. 164 and 165, or any one of SEQ ID NOs. 164 and 165, and each of these polynucleotides are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, or 89% identical. , polynucleotides that are 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical, SEQ ID NOs. 166 and 167, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 210 and 211, or polynucleotides that are at least 80% identical to either SEQ ID NOs. 210 and 211, Polynucleotides identical to 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of each, SEQ ID NOs. 212 and 213, or polynucleotides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of each, SEQ ID NOs. 214 and 215,Or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 214 and 215, respectively, or at least 8 SEQ ID NOs. 216 and 217, respectively. Polynucleotides that are 0%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical, SEQ ID NOs. 218 and 219, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88% identical to either SEQ ID NOs. 218 or 219. Polynucleotides that are identical by %, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 218 and 226, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96% respectively. A polynucleotide that is identical by %, 97%, 98%, or 99%, or a polynucleotide that is identical by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively to SEQ ID NOs. In some embodiments, the immunogenic composition comprises a first and second polynucleotide or a first and second viral vector or a first and second lipoplex (e.g., LNP) comprising the following first and second polynucleotides: (a) a first vector or a first lipoplex (e.g., LNP) comprising a first and second polynucleotide comprising the polynucleotides SEQ ID NOs. 131 and 135, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 131 or 135, respectively.(b) A second vector or second lipoplex (e.g., LNP) comprising the first and second polynucleotides comprising SEQ ID NOs: 133 and 137, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs: 133 or 137, respectively. In some embodiments, the immunogenic composition comprises a first and second polynucleotide or a first and second viral vector or a first and second lipoplex (e.g., LNP) comprising the following first and second polynucleotides: (a) the first and second polynucleotides comprising SEQ ID NOs. 139 and 145, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, (b) a first vector or first lipoplex (e.g., LNP) containing a polynucleotide that is 98% or 99% identical to (a) a first and second polynucleotide containing SEQ ID NOs. 142 and 148, or a second vector or second lipoplex (e.g., LNP) containing a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 142 or 148. In some embodiments, the immunogenic composition comprises a first and second polynucleotide or a first and second viral vector or a first and second lipoplex (e.g., LNP) comprising the following first and second polynucleotides: (a) a first vector or a first lipoplex (e.g., LNP) comprising a first and second polynucleotide comprising the polynucleotides SEQ ID NOs. 140 and 146, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 140 or 146, respectively.(b) A second vector or second lipoplex (e.g., LNP) comprising a first and second polynucleotide comprising the sequence numbers 143 and 149, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either one of the sequence numbers 143 and 149. In some embodiments, the first and second viral vectors of such an immunogenic composition are lymphocytic choriomeningitis mammalenavirus (LCMV) viral vectors. In some embodiments, the immunogenic composition comprises a first and second polynucleotide or a first and second viral vector or a first and second lipoplex (e.g., LNP) comprising the following first and second polynucleotides and second polynucleotides: (a) the first and second polynucleotides comprising SEQ ID NOs. 150 and 152, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 150 or 152. (b) a first vector or first lipoplex (e.g., LNP) comprising a polynucleotide; (b) a first and second polynucleotide comprising SEQ ID NOs: 154 and 157 or SEQ ID NOs: 155 and 158, or a second vector or second lipoplex (e.g., LNP) which is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 154 and 157 or SEQ ID NOs: 155 and 158. In some embodiments, the first and second viral vectors of such immunogenic composition are Kalimanmalenavirus (also known as Pitchin de Mammamalenavirus or Pitchin de Arenavirus) viral vectors. In some embodiments, the immunogenic composition comprises the following first polynucleotide and second polynucleotide:The first and second polynucleotides or the first and second viral vectors or the first and second lipoplexes (e.g., LNPs) comprises: (a) the first and second polynucleotides comprising SEQ ID NOs. 151 and 153, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% respectively, (b) a first viral vector or first lipoplex (e.g., LNP) containing a polynucleotide that is 99% identical to or (c) a first and second polynucleotide containing SEQ ID NOs. 156 and 159, or a second viral vector or second lipoplex (e.g., LNP) containing a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 156 or 159. In some embodiments, the immunogenic composition comprises a first and second polynucleotide or a first and second viral vector or a first and second lipoplex (e.g., LNP) comprising one or more polynucleotides: (a) the polynucleotide of SEQ ID NO: 160, or SEQ ID NO: 160 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% (b) a first viral vector or first lipoplex (e.g., LNP) containing the same polynucleotide; (b) the polynucleotide of SEQ ID NO: 161, or a second viral vector or second lipoplex (e.g., LNP) containing the same polynucleotide as SEQ ID NO: 161, each being at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 161.In some embodiments, the immunogenic composition comprises a first and second polynucleotide or a first and second viral vector or a first and second lipoplex (e.g., LNP) comprising one or more polynucleotides: (a) the polynucleotide of SEQ ID NO: 162, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of SEQ ID NO: 162 (b) a first viral vector or first lipoplex (e.g., LNP) containing the same polynucleotide, (b) the polynucleotide of SEQ ID NO: 163, or a second viral vector or second lipoplex (e.g., LNP) containing the same polynucleotide as SEQ ID NO: 163, each being at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 163. In some embodiments, the immunogenic composition comprises a first and second polynucleotide or a first and second viral vector or a first and second lipoplex (e.g., LNP) comprising one or more polynucleotides: (a) the polynucleotide of SEQ ID NO: 164, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% (b) a first viral vector or first lipoplex (e.g., LNP) containing the same polynucleotide; (b) the polynucleotide of SEQ ID NO: 165, or a second viral vector or second lipoplex (e.g., LNP) containing the same polynucleotide as SEQ ID NO: 165, each being at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 165.In some embodiments, the immunogenic composition comprises a first and second polynucleotide or a first and second viral vector or a first and second lipoplex (e.g., LNP) comprising one or more polynucleotides: (a) the polynucleotide of SEQ ID NO: 166, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% (b) a first viral vector or first lipoplex (e.g., LNP) containing the same polynucleotide, (b) the polynucleotide of SEQ ID NO: 167, or a second viral vector or second lipoplex (e.g., LNP) containing the same polynucleotide as SEQ ID NO: 167, each being at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 167. In some embodiments, the immunogenic composition comprises a first and second polynucleotide or a first and second viral vector or a first and second lipoplex (e.g., LNP) comprising one or more polynucleotides: (a) the polynucleotide of SEQ ID NO: 210, or SEQ ID NO: 210 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% (b) a first viral vector or first lipoplex (e.g., LNP) containing the same polynucleotide; (b) a second viral vector or second lipoplex (e.g., LNP) containing the polynucleotide of SEQ ID NO: 211, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 211.In some embodiments, the immunogenic composition comprises a first and second polynucleotide or a first and second viral vector or a first and second lipoplex (e.g., LNP) comprising one or more polynucleotides: (a) the polynucleotide of SEQ ID NO: 212, or SEQ ID NO: 212 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% (b) a first viral vector or first lipoplex (e.g., LNP) containing the same polynucleotide; (b) a polynucleotide of SEQ ID NO: 213, or a second viral vector or second lipoplex (e.g., LNP) containing the same polynucleotide as SEQ ID NO: 213 by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%. In some embodiments, the immunogenic composition comprises a first and second polynucleotide or a first and second viral vector or a first and second lipoplex (e.g., LNP) comprising one or more polynucleotides: (a) the polynucleotide of SEQ ID NO: 214, or SEQ ID NO: 214 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% (b) a first viral vector or first lipoplex (e.g., LNP) containing the same polynucleotide; (b) a second viral vector or second lipoplex (e.g., LNP) containing the polynucleotide of SEQ ID NO: 215, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 215.In some embodiments, the immunogenic composition comprises a first and second polynucleotide or a first and second viral vector or a first and second lipoplex (e.g., LNP) comprising one or more polynucleotides: (a) the polynucleotide of SEQ ID NO: 216, or SEQ ID NO: 216 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% (b) a first viral vector or first lipoplex (e.g., LNP) containing the same polynucleotide; (b) a second viral vector or second lipoplex (e.g., LNP) containing the polynucleotide of SEQ ID NO: 217, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 217. In some embodiments, the immunogenic composition comprises a first and second polynucleotide or a first and second viral vector or a first and second lipoplex (e.g., LNP) comprising one or more polynucleotides: (a) the polynucleotide of SEQ ID NO: 218, or SEQ ID NO: 218 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% (b) a first viral vector or first lipoplex (e.g., LNP) containing the same polynucleotide; (b) a second viral vector or second lipoplex (e.g., LNP) containing the polynucleotide of SEQ ID NO: 219, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 219.In some embodiments, the immunogenic composition comprises a first and second polynucleotide or a first and second viral vector or a first and second lipoplex (e.g., LNP) comprising one or more polynucleotides: (a) the polynucleotide of SEQ ID NO: 218, or SEQ ID NO: 218 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% (b) a first viral vector or first lipoplex (e.g., LNP) containing the same polynucleotide; (b) a second viral vector or second lipoplex (e.g., LNP) containing the polynucleotide of SEQ ID NO: 226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 226. In some embodiments, the immunogenic composition comprises a first and second polynucleotide or a first and second viral vector or a first and second lipoplex (e.g., LNP) comprising one or more polynucleotides: (a) the polynucleotide of SEQ ID NO: 225, or SEQ ID NO: 225 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% (b) a first viral vector or first lipoplex (e.g., LNP) comprising the same polynucleotide, (b) the polynucleotide of SEQ ID NO: 226, or a second viral vector or second lipoplex (e.g., LNP) comprising the polynucleotide of SEQ ID NO: 226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 226. In some embodiments, the immunogenic composition is a vector or lipoplex comprising a complex fusion polypeptide and a polynucleotide encoding the complex fusion polypeptide. A complex fusion polypeptide comprises (e.g., LNP) and contains, or consists of, an amino acid sequence which is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of the amino acid sequences 105-112, 200-209, 222-223, and 227. In some embodiments, the immunogenic composition comprises a complex fusion polypeptide and a vector or lipoplex (e.g., LNP) containing a polynucleotide encoding the complex fusion polypeptide, wherein the complex fusion polypeptide contains, or comprises, an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 209, 222, and 223. In some embodiments, one or more fusion polypeptides do not include Gag 54-146, Gag 370-500, Pol 1-55, Pol 118-128, Pol 321-366, Pol 432-541, Pol 607-682, Pol 709-746, Pol 828-839, Pol 921-931, Nef 1-63, Nef 100-116, and Nef 149-206, or any polypeptide segments corresponding to these fragments or subsequences, where the amino acid position numbers of Gag, Pol, and Nef correspond to SEQ ID NOs. 1, 2, and 3, respectively. In some embodiments, one or more fusion polypeptides do not contain a polypeptide segment having an amino acid sequence, or a fragment or subsequence thereof, of any one of SEQ ID NOs: 35-47, or any fragment or subsequence thereof, or an amino acid sequence, or a fragment or subsequence thereof, that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 35-47.In various embodiments of the immunogenic composition, the first and second viral vectors may be lymphocytic choriomeningitis mammalenavirus (LCMV) viral vectors, Kali mammalenavirus (also known as pitin de mammalenavirus or pitin de arenavirus) viral vectors, or adenovirus vectors, such as chimpanzee adenovirus vectors (ChAds). In some embodiments, the immunogenic composition comprises a single vector containing one or more polynucleotides encoding the first and second fusion polypeptides. In some embodiments, the immunogenic composition further comprises one or more of the following: auxiliaries, detergents, micelle-forming agents, and oils. In some embodiments, the immunogenic composition is formulated for administration via routes selected from intravenous, intramuscular, intradermal, subcutaneous, intranodular, and intramucosal (e.g., cheek, nasal cavity, rectal, vaginal). In some embodiments, the immunogenic composition is formulated as a liquid, suspension, or emulsion. In some embodiments, the immunogenic composition is lyophilized.

[0015] There is further provided a kit comprising one or more unit doses of one or more of the fusion polypeptides, one or more of the composite fusion polypeptides, one or more of the polynucleotides, one or more of the vectors, or one or more of the immunogenic compositions described herein. In some embodiments, the kit comprises two or more of the fusion polypeptides described herein, two or more of the composite fusion polypeptides, two or more of the polynucleotides, two or more of the vectors, or two or more of the immunogenic compositions. In some embodiments, the one or more unit doses are in a single container. In some embodiments, the one or more unit doses are in two or more separate containers. In some embodiments, the kit comprises one or more containers selected from vials, ampoules, and pre-filled syringes. In some embodiments, the kit comprises one or more containers containing one or more of the fusion polypeptides, one or more of the polynucleotides, or one or more of the vectors in an aqueous solution. In some embodiments, the one or more unit doses are the same. In some embodiments, the one or more unit doses are different. In some embodiments, the kit comprises one or more unit doses of one or more viral vectors, and the unit dose is about 10 3 ~ about 10 12 viral focus forming units (FFU) or plaque forming units (PFU) or infectious units (IU) or viral particles (vp), e.g., about 10 4 ~ about 10 7 viral FFU or PFU or IU or vp, e.g., about 10 3 ~ about 10 4 , 10 5 , 10 6 , 10 7 , 10 8 , 10 9 , 10 10 , 10 11 , 10 12 , 10 13 , 10 14 or 10 15The viral FFU or PFU or IU or vp range. In some embodiments, the kit comprises one or more vectors comprising a first fusion polypeptide and a second fusion polypeptide, or one or more polynucleotides encoding the first and second fusion polypeptides, wherein the first and second polypeptides comprise the following polypeptide segments optionally linked or connected by one or more linkers from the N-terminus to the C-terminus: SEQ ID NOs. 6, 4, 16, and 26, and SEQ ID NOs. 7, 5, 27, and 17, SEQ ID NOs. 12, 24, 8, and 10, and SEQ ID NOs. 9, 25, 13, and 11, SEQ ID NOs. 14, 22, 18, 24, and 20, and sequence numbers 15, 25, 19, 23, and 21, sequence numbers 26, 16, 4, and 6, and sequence numbers 7, 27, 5, and 17, sequence numbers 8, 24, 12, and 10, and sequence numbers 13, 25, 9, and 11, sequence numbers 22, 24, 14, 18, and 20, and sequence numbers 25, 23, 15, 21, and 19, sequence numbers 20, 6, 4, 18, 16, and 26, and sequence numbers 7, 19, 5, 21, 27, and 17, sequence numbers 8, 24, 14, 12, 22, and 10, and sequence numbers 9, 13, 25, 23, 15, and 11, SEQ ID NOs: 18, 26, 20, 4, 6, and 16, and SEQ ID NOs: 7, 21, 17, 5, 27, and 19, SEQ ID NOs: 22, 24, 12, 14, 8, and 10, and SEQ ID NOs: 15, 25, 9, 23, 13, and 11, SEQ ID NOs: 24, 6, 4, 20, 18, and 32, and SEQ ID NOs: 8, 30, 14, 12, 26, and 10, SEQ ID NOs: 24, 6, 4, 20, 18, and 32, and SEQ ID NOs: 7, 21, 5, 25, 33, and 19, SEQ ID NOs: 24, 6, 4, 20, 18, and 32, and SEQ ID NOs: 8, 30, 14, 12, 2 6, and 10, SEQ ID NOs: 8, 30, 14, 12, 26, and 10, and SEQ ID NOs: 9, 13, 31, 27, 15, and 11, SEQ ID NOs: 6, 20, 4, 24, 32, and 18, and SEQ ID NOs: 8, 12, 30, 26, 14, and 10, SEQ ID NOs: 7, 21, 5, 25, 33, and 19, and SEQ ID NOs: 9, 13, 31, 27, 15, and 11, SEQ ID NOs: 20, 32, 24, 4, 6, and 18, and SEQ ID NOs: 26, 30, 12, 14, 8, and 10, SEQ ID NOs: 7, 25, 19, 5, 33, and 21, and SEQ ID NOs: 15, 31, 9, 27, 13,and 11, SEQ ID NOs: 24, 6, 16, and 18, and SEQ ID NOs: 26, 20, 10, and 28, SEQ ID NOs: 24, 6, 16, and 18, and SEQ ID NOs: 26, 10, 20, and 28, SEQ ID NOs: 24, 6, 16, and 18, and SEQ ID NOs: 7, 25, 17, and 19, SEQ ID NOs: 7, 19, 17, and 25, and SEQ ID NOs: 21, 27, 11, and 29, SEQ ID NOs: 24, 16, 6, and 18, and SEQ ID NOs: 27, 11, 21, and 29, SEQ ID NOs: 7, 25, 17, and 19, and SEQ ID NOs: 11, 27, 21, and 29, sequence numbers 7, 25, 17, and 19, and sequence numbers 21, 27, 11, and 29, sequence numbers 22, 6, 20, and 28, and sequence numbers 23, 7, 21, and 29, sequence numbers 22, 20, 6, and 28, and sequence numbers 7, 21, 23, and 29, sequence numbers 26, 10, 20, and 28, and sequence numbers 21, 27, 11, and 29, sequence numbers 22, 6, 16, 20, 18, 28, 26, and 10, or sequence numbers 7, 21, 19, 17, 27, 25, 29, and 11. In some embodiments, the kit comprises one or more vectors or one or more lipoplexes (LNPs) comprising one or more fusion polypeptides, one amino acid sequence among SEQ ID NOs. 70-101, 105-112, 200-209, 222-223, and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs. In some embodiments, the immunogenic composition comprises one or more fusion polypeptides, one amino acid sequence of any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209, and 222-223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs: 82-83, 85-87, 98-101, 209, and 222-223.Alternatively, the kit comprises one or more vectors or one or more lipoplexes (LNPs) comprising one or more polynucleotides encoding one or more fusion polypeptides, or the following: a first fusion polypeptide and a second fusion polypeptide, or a vector comprising one or more polynucleotides encoding the following first fusion polypeptide and a second fusion polypeptide, optionally linked or connected by one or more linkers: SEQ ID NOs. 70 and 71, or one of SEQ ID NOs. 70 and 71, each comprising at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, and 92%. A fusion polypeptide that is 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 72 and 73, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 74 and 75, or a fusion polypeptide that is at least 80%, 81%, 82% identical to either SEQ ID NOs. 74 and 75. Fusion polypeptides identical to %, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 76 and 77, or fusion polypeptides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively, SEQ ID NOs. 78 and 77 9, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 80 and 81, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, respectively.A fusion polypeptide that is 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 82 and 83, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 84 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, or 89% identical to either SEQ ID NOs. 84 and 85, Fusion polypeptides that are 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 86 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 88 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, or 8% identical to Fusion polypeptides that are 4%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 82 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 82 and 8695%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. Fusion polypeptides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 82 and 88, or fusion polypeptides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively, SEQ ID NOs. 83 and 87,Or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 83 and 87, or at least 80%, 81%, or 82% identical to either SEQ ID NOs. 85 and 87, respectively. , fusion polypeptides that are 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical, SEQ ID NOs. 88 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, respectively identical to fusion polypeptides, SEQ ID NOs. 88 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, Fusion polypeptides that are identical by %, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, to SEQ ID NOs. 84 and 88, or to each of SEQ ID NOs. 84 and 88 by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, to each of SEQ ID NOs. 85 and 89, or to each of SEQ ID NOs. 85 and 89 by at least 80%, 81%, 82%, 83%, 84%, 85%, or 86%, A fusion polypeptide that is 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 85 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 90 and 91, or at least 80% identical to either SEQ ID NOs. 90 and 91, Fusion polypeptides identical to 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 92 and 93, or fusion polypeptides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 94 and 95, or SEQ ID NOs. 94 and 95 A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of the five, SEQ ID NOs. 96 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of the five,Fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 95 and 97, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 9 Fusion polypeptides that are 6%, 97%, 98%, or 99% identical to SEQ ID NOs. 220 and 221, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or 8% identical to one of SEQ ID NOs. 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or 8% identical to one of SEQ ID NOs. 98 and 100. Fusion polypeptides identical to 7%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of SEQ ID NOs. 99 and 101, or fusion polypeptides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of either SEQ ID NOs. 98 and 99, or fusion polypeptides identical to at least one of SEQ ID NOs. 98 and 99, or fusion polypeptides identical to at least one of SEQ ID NOs. 98 and 99, or fusion polypeptides identical to at least one of SEQ ID NOs. A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 100 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs.One or more vectors or one or more lipoplexes (e.g., LNPs) comprising the following first fusion polypeptide and second fusion polypeptide, and one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally linked or connected from the N-terminus to the C-terminus by one or more linkers: SEQ ID NOs. 70 and 71, or one of SEQ ID NOs. 70 and 71, each comprising at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92% A fusion polypeptide that is identical to %, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 71 and 70, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 72 and 73, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, 84%, or 85%, one of SEQ ID NOs. 72 and 73, Fusion polypeptides that are 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 73 and 72, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 74 and 75 Fusion polypeptides that are identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 75 and 74, or fusion polypeptides that are identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively, SEQ ID NOs. 76 and 77,Or a fusion polypeptide identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of either SEQ ID NOs. 76 and 77, respectively, or a fusion polypeptide identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of either SEQ ID NOs. A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a fusion polypeptide, SEQ ID NOs. 78 and 78, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, or 959, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, or 95% identical to a fusion polypeptide, SEQ ID NOs. , 96%, 97%, 98%, or 99% identical fusion polypeptide, SEQ ID NOs. 80 and 81, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical fusion polypeptide, SEQ ID NOs. 81 and 80, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 9 A fusion polypeptide that is 0%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 82 and 83, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 83 and 82, or at least 80%, 81%, 82%, 83%, 84%,Fusion polypeptides that are 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 84 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 85 and 8495%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 85 and 84, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 85%, 86%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 85 and 84 Fusion polypeptides that are 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to both SEQ ID NOs. 86 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 86 and 87, respectively, or sequence number Fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either one of numbers 87 and 86, respectively; SEQ ID NOs. 88 and 89; or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either one of SEQ ID NOs. 88 and 89, respectively. Lipeptides, fusion polypeptides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of either SEQ ID NOs. 82 and 85, fusion polypeptides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, or 96% of either SEQ ID NOs. 82 and 85,A fusion polypeptide that is 97%, 98%, or 99% identical to SEQ ID NOs. 85 and 82, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 85 or 82, respectively. A fusion polypeptide that is identical to SEQ ID NOs. 82 and 86, or to any one of SEQ ID NOs. 82 and 86 by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively; a fusion polypeptide that is identical to SEQ ID NOs. 86 and 82, or to any one of SEQ ID NOs. 86 and 82 by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, or 99%; a fusion polypeptide that is identical to any one of SEQ ID NOs. 82 and 86, or to any one of SEQ ID NOs. 86 and 82, or to any one of SEQ ID NOs. 86 and 82, by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, or 99%; A fusion polypeptide that is 4%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 82 and 88, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 88 and 82, or at least 80%, 81%, 82%, 83%, 84%, 85%, or 86% identical to either SEQ ID NOs. 88 and 82, Fusion polypeptides that are 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 83 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 87 and 83 Fusion polypeptides, SEQ ID NOs. 85 and 87, which are 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical, respectively, or fusion polypeptides, SEQ ID NOs. 85 and 85, which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 85 and 87, respectively,Or a fusion polypeptide identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of either SEQ ID NOs. 87 and 88, or identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of either SEQ ID NOs. 88 and 87, or identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of either SEQ ID NOs. A fusion polypeptide that is identical to SEQ ID NOs. 87 and 88, or one of SEQ ID NOs. 87 and 88, by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively, a fusion polypeptide that is identical to SEQ ID NOs. 84 and 88, or one of SEQ ID NOs. 88 and 84, by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, or 95%. A fusion polypeptide that is identical to %, 96%, 97%, 98%, or 99% of Sequence ID No. 88 and 84, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of Sequence ID No. 85 and 89, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, or 89% of Sequence ID No. 85 and 89, A fusion polypeptide that is 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 89 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 85 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, or 99% identical to either SEQ ID NOs. 85 and 101,A fusion polypeptide that is 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 101 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 90 and 91 Fusion polypeptides, SEQ ID NOs. 91 and 90, which are identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% respectively, SEQ ID NOs. 91 and 90, or fusion polypeptides, SEQ ID NOs. 92 and 90, which are identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% respectively, SEQ ID NOs. 92 and 90 3. A fusion polypeptide which is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 92 and 93, respectively; or a fusion polypeptide which is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 93 and 92, respectively. A fusion polypeptide that is identical to SEQ ID NOs. 94 and 95, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 95 and 94, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%,Fusion polypeptides that are 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 96 and 97, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 97 and 96, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, respectively. Fusion polypeptides that are 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 94 and 96, or each of SEQ ID NOs. 94 and 96, and each of them are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 96 and 94, or each of SEQ ID NOs. 96 and 94, and each of them are at least 80%, 81%, 82%, Fusion polypeptides identical to 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of SEQ ID NOs. 95 and 97, or fusion polypeptides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of either SEQ ID NOs. 97 and 95, or either SEQ ID NOs. 97 and 95. A fusion polypeptide that is identical to one of the following by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively, SEQ ID NOs. 220 and 221, or a fusion polypeptide that is identical to one of the following by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively,Fusion polypeptides identical to SEQ ID NOs. 221 and 220, or any one of SEQ ID NOs. 221 and 220 by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively; SEQ ID NOs. 98 and 100, or any one of SEQ ID NOs. 98 and 100, are identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, or 95%; Fusion polypeptides identical to SEQ ID NOs. 221 and 220, or any one of SEQ ID NOs. 221 and 220, respectively; Fusion polypeptides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, or 95% A fusion polypeptide that is identical to %, 96%, 97%, 98%, or 99% of SEQ ID NOs. 100 and 98, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of either SEQ ID NOs. 99 and 101, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or 87 A fusion polypeptide that is identical to %, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of SEQ ID NOs. 101 and 99, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of either SEQ ID NOs. 98 and 99, or at least one of SEQ ID NOs. 98 and 99 Fusion polypeptides identical to 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 99 and 98, or fusion polypeptides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 100 and 101,Or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 101 and 100, or at least 80%, 81%, identical to either SEQ ID NOs. 101 and 100, or either SEQ ID NOs. 101 and 100. A fusion polypeptide that is 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical. In some embodiments, the kit comprises a first, second, third, and fourth viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: (a) a first and second fusion polypeptide comprising SEQ ID NOs. 82 and 83, or at least 80%, 81%, 82%, 83%, and 84% identical to either SEQ ID NOs. 82 and 83, respectively. (b) a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide that is identical to, (b) a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs. 84 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 8 (c) A second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide that is identical to 7%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively; (c) a first fusion polypeptide comprising SEQ ID NOs. 86 and 87, and a second fusion polypeptide comprising at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, one of SEQ ID NOs. 86 and 87, respectively. (d) A third viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide that is identical by %, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively, (d) a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs. 88 and 89, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%,A fourth viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide that is 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical. In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: (a) the first and second fusion polypeptides comprising SEQ ID NOs. 82 and 86, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. (b) a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding identical fusion polypeptides; (b) a first fusion polypeptide comprising SEQ ID NOs. 83 and 87 and a second fusion polypeptide, or a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 83 or 87. In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: (a) the first and second fusion polypeptides comprising SEQ ID NOs. 82 and 85, or one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 82 or 85, respectively.(b) a first viral vector or lipoplex (e.g., LNP), (b) a first fusion polypeptide comprising SEQ ID NOs. 88 and 87 and a second fusion polypeptide, or a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 88 or 87, respectively. In some embodiments, the kit comprises a first and second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: (a) the first and second fusion polypeptides comprising SEQ ID NOs. 82 and 88, or one of SEQ ID NOs. 82 and 88, each in amounts of at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% (b) a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding identical fusion polypeptides; (b) a first fusion polypeptide comprising SEQ ID NOs. 85 and 87 and a second fusion polypeptide, or a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 85 or 87. In some embodiments, the kit comprises a first and second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: (a) a fusion polypeptide comprising SEQ ID NO: 200, or SEQ ID NO: 200 and at least 80%, 81%, 82%, 83%,(b) a first viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide that is 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to (b) a fusion polypeptide comprising SEQ ID NO: 201, or a second viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 201. In some embodiments, the kit comprises a first and second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: (a) a fusion polypeptide comprising SEQ ID NO: 202, or SEQ ID NO: 202 in an amount of at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or (b) a first viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide that is 99% identical to (b) SEQ ID NO: 203, or a second viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 203. In some embodiments, the kit comprises a first and second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: (a) a fusion polypeptide comprising SEQ ID NO: 204, or SEQ ID NO: 204 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%,(b) a first viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide that is 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to (a) a fusion polypeptide comprising SEQ ID NO: 205, or a second viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 205. In some embodiments, the kit comprises a first and second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: (a) a fusion polypeptide comprising SEQ ID NO: 105 or 206, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or (b) a first viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide that is 99% identical to (a) SEQ ID NO: 107 or 207, or a second viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 107 or 207, respectively. In some embodiments, the kit comprises a first and second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: (a) a fusion polypeptide comprising SEQ ID NO: 208, or SEQ ID NO: 208 and at least 80%, 81%, 82%,(b) a first viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide that is 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical, (b) SEQ ID NO: 209 or, A second viral vector or lipoplex (e.g., LNP) comprising a fusion polypeptide including SEQ ID NO: 227, or a polynucleotide encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 209 or SEQ ID NO: 227. In some embodiments, the kit comprises a first and second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: (a) a fusion polypeptide comprising SEQ ID NO: 222, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 222. (b) a first viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide, (b) a fusion polypeptide comprising SEQ ID NO: 209 or SEQ ID NO: 227, or a second viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 209 or SEQ ID NO: 227. In some embodiments, the kit comprises a first and second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: (a) a fusion polypeptide comprising SEQ ID NO: 222, or a polynucleotide encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 222.(b) a first viral vector or lipoplex (e.g., LNP), (b) a fusion polypeptide comprising SEQ ID NO: 223, or a second viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 223. In some embodiments, the kit comprises first, second, third, and fourth viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; (b) a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 83 and 87 (c) a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to (c) SEQ ID NOs. 84 and 88 A third viral vector or lipoplex (e.g.,) comprising one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the first fusion polypeptide and the second fusion polypeptide, or to one of SEQ ID NOs. 84 and 88, respectively.(d) a first fusion polypeptide and a second fusion polypeptide comprising LNP), (d) a first fusion polypeptide comprising SEQ ID NOs. 85 and 89, or a second fusion polypeptide comprising one or more polynucleotides encoding a fusion polypeptide which is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 85 and 89, respectively. In some embodiments, the kit comprises first, second, third, and fourth viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either one of sequence numbers 82 and 86, respectively; (b) a first fusion polypeptide comprising sequence numbers 83 and 87 A second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 83 and 87, respectively. (c) comprising a first fusion polypeptide and a second fusion polypeptide including SEQ ID NOs. 98 and 100, or one or more polynucleotides encoding a fusion polypeptide which is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 98 and 100, respectively.A third viral vector or lipoplex (e.g., LNP), (d) a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs. 85 and 101, or a fourth viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 85 and 101, respectively. In some embodiments, the kit comprises a first, second, third, and fourth viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either one of SEQ ID NOs: 82 and 86, respectively; (b) One or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide containing SEQ ID NOs. 83 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 83 or 87, respectively. (c) a second viral vector or lipoplex (e.g., LNP) containing tide, (c) a first fusion polypeptide and a second fusion polypeptide containing SEQ ID NOs. 98 and 100, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,(d) a third viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide that is 98% or 99% identical to (d) a first fusion polypeptide comprising SEQ ID NOs. 99 and 101 and a second fusion polypeptide, or a fourth viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 99 or 101, respectively. In some embodiments, the kit comprises a first and second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: (a) the first and second fusion polypeptides comprising SEQ ID NOs. 90 and 91, or one of SEQ ID NOs. 90 and 91, each in amounts of at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% (b) a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding identical fusion polypeptides, (b) a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs. 92 and 93, or a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 92 and 93, respectively. In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers.(LNP) comprising: (a) the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NOs: 94 and 96, or one or more polynucleotides encoding a fusion polypeptide which is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs: 94 and 96, respectively. (b) a first viral vector or lipoplex (e.g., LNP), (b) a first fusion polypeptide and a second fusion polypeptide comprising the following sequence numbers 95 and 97, or a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of sequence numbers 95 and 97, respectively. In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: (a) the following first and second fusion polypeptides comprising SEQ ID NOs. 220 and 221, or one of SEQ ID NOs. 220 and 221, each comprising at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 9% (b) a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide that is 9% identical; (b) a first fusion polypeptide comprising the following first and second fusion polypeptides, comprising SEQ ID NOs. 95 and 97, or a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 95 or 97, respectively. In some embodiments, the kit comprises a first and second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: (a) the following first and second fusion polypeptides comprising SEQ ID NOs. 94 and 95,(b) The following first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide which is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 94 and 95, respectively, (b) the following first viral vector or lipoplex (e.g., LNP) comprising SEQ ID NOs. 96 and 97 A second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the fusion polypeptide and the second fusion polypeptide, or to one of SEQ ID NOs. 96 and 97, respectively. In some embodiments, the kit comprises a first and second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: (a) the first and second fusion polypeptides comprising SEQ ID NOs. 98 and 100, or one of SEQ ID NOs. 98 and 100, each in amounts of at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% (b) a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding identical fusion polypeptides, (b) a first fusion polypeptide comprising SEQ ID NOs. 99 and 101 and a second fusion polypeptide, or a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 99 and 101, respectively. In some embodiments, the kit is:The first, second, third, and fourth viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: (a) the first and second fusion polypeptides comprising SEQ ID NOs. 94 and 96, or one of SEQ ID NOs. 94 and 96, each comprising at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 9 (b) a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide that is 4%, 95%, 96%, 97%, 98%, or 99% identical; (b) a first fusion polypeptide comprising SEQ ID NOs. 95 and 97, and a second fusion polypeptide, or each of SEQ ID NOs. 95 and 97, which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical. (c) a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide, (c) a first fusion polypeptide comprising SEQ ID NOs. 98 and 100 and a second fusion polypeptide, or one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 98 and 100. (d) a third viral vector or lipoplex (e.g., LNP), (d) a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 99 and 101, or a fourth viral vector or lipoplex (e.g.,(LNP). In some embodiments, the kit comprises first, second, third, and fourth viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: (a) the first and second fusion polypeptides comprising SEQ ID NOs. 94 and 95, or one of SEQ ID NOs. 94 and 95 with at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89% (b) A first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide that is identical to, (b) a first fusion polypeptide comprising SEQ ID NOs. 96 and 97, and a second fusion polypeptide, or one of SEQ ID NOs. 96 and 97, respectively, by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96% (c) A second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide that is identical to (c) a first fusion polypeptide comprising SEQ ID NOs. 98 and 99, and a second fusion polypeptide, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of either SEQ ID NOs. A third viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide, (d) a first fusion polypeptide comprising SEQ ID NOs. 100 and 101 and a second fusion polypeptide comprising one or more polynucleotides encoding a fusion polypeptide which is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 100 and 101, respectively.A fourth viral vector or lipoplex (e.g., LNP). In various embodiments of the kit, the first and second viral vectors are lymphocytic choriomeningitis mammalenavirus (LCMV) viral vectors, Kali mammalenavirus (also known as pitin de mammalenavirus or pitin de arenavirus) viral vectors, or adenovirus vectors, such as chimpanzee adenovirus vectors (ChAds). In some embodiments, the kit includes, or includes, a polynucleotide comprising, one nucleic acid sequence among sequence numbers 130-167, 210-219, and 225-226, or a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to one of sequence numbers 130-167, 210-219, and 225-226. In some embodiments, the kit includes, or comprises, a polynucleotide consisting of, a nucleic acid sequence which is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 95%, 96%, 97%, 98%, or 99% identical to any one of the nucleic acid sequences 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225, or 99% identical to any one of the and 226. In some embodiments, the kit comprises one or more vectors or lipoplexes (e.g., LNPs) containing the following first polynucleotides and second polynucleotides: polynucleotides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of either SEQ ID NOs: 130 and 134, or polynucleotides identical to at least 80%, 81%, or either SEQ ID NOs: 130 and 134.Polynucleotides that are identical by 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively, SEQ ID NOs. 131 and 133, or at least 80%, 81%, 82%, 83%, 84%, 85%, 8, Polynucleotides that are 6%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 131 and 135, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 132 and 13695%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. Polynucleotides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of each, SEQ ID NOs. 133 and 135, or polynucleotides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of each, SEQ ID NOs. 133 and Polynucleotides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of each of sequence numbers 134 and 136, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% of each of sequence numbers 134 and 136. Polynucleotides that are % or 99% identical, SEQ ID NOs. 135 and 137, or any one of SEQ ID NOs. 135 and 137, and each of these, at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical, polynucleotides that are % or 99% identical, SEQ ID NOs. 138 and 141, or any one of SEQ ID NOs. 138 and 141, and each of these, at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, or 90%,Polynucleotides that are 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 138 and 144, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 139 and 142, or polynucleotides that are at least 80%, 81%, 82%, 83 Polynucleotides identical by %, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 139 and 145, or polynucleotides identical by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively, SEQ ID NOs. 140 and 146, or SEQ ID NOs. 140 and 146 Polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of them; SEQ ID NOs: 142 and 148; or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of them; or 99% identical to any one of them; polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 95%, 96%, 97%, 98%, or 99% identical to any one of them; polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, D, polynucleotides identical to SEQ ID NOs. 143 and 149, or any one of SEQ ID NOs. 143 and 149 by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively, polynucleotides identical to SEQ ID NOs. 145 and 148, or any one of SEQ ID NOs. 145 and 148, by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, respectively,Polynucleotides that are 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 150 and 152, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 150 and 155, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or 87% identical to7% identical to at least 87% identical to at least 87% identical to at least 87% identical to at least 87% identical to at least 87% identical to at least 87% identical to at least 97%, 98%, or 99% identical to SEQ ID NOs. 150 and 155, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or 87% identical to at least 87% identical to at least 97%, 98%, or 99% identical to SEQ ID NOs. Polynucleotides that are 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 151 and 153, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 151 and 156 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 151 and 156, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 151 and 156, or at least 80%, 81%, 82%, 83%, 84%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ Polynucleotides identical to both SEQ ID NOs. 152 and 158 by 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively, SEQ ID NOs. 152 and 158, or polynucleotides identical to either SEQ ID NOs. 152 and 158 by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively, SEQ ID NOs. 153 and Polynucleotides identical to 159, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of either SEQ ID NOs. 154 and 157, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, respectively,Polynucleotides that are 98% or 99% identical to SEQ ID NOs. 155 and 158, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 156 and 159, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 8 Polynucleotides that are 9%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical, SEQ ID NOs. 160 and 161, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 162 and 163, or polynucleotides that are at least 80% identical to either SEQ ID NOs. 162 and 163, or polynucleotides that are at least 80% identical to either SEQ ID NOs. 162 and 163 Polynucleotides identical by %, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 164 and 165, or polynucleotides identical by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively, SEQ ID NOs. 166 and 165 7, or polynucleotides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of either SEQ ID NOs. 166 and 167, respectively, SEQ ID NOs. 210 and 211, or polynucleotides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,Polynucleotides that are 98% or 99% identical, SEQ ID NOs. 212 and 213, or any one of SEQ ID NOs. 212 and 213, and each polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical, SEQ ID NOs. 214 and 215, or any one of SEQ ID NOs. 214 and 215, and each polynucleotide that is at least 80%, 81%, Polynucleotides that are 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical, SEQ ID NOs. 216 and 217, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to each other. Polynucleotides identical to a certain polynucleotide, SEQ ID NOs. 218 and 219, or any one of SEQ ID NOs. 218 and 219 by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively, SEQ ID NOs. 218 and 226, or any one of SEQ ID NOs. 218 and 226, by at least 80%, 81%, 82%, 83%, 84%, 85%, respectively. A polynucleotide that is identical by 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively, or a polynucleotide that is identical by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively. In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising the following first and second polynucleotides: (a) the first and second polynucleotides comprising the(b) a first vector or lipoplex (e.g., LNP) comprising a polynucleotide which is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs: 131 or 135, respectively, (b) the first and second, A second vector or lipoplex (e.g., LNP) containing a polynucleotide having sequence numbers 133 and 137, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either sequence number 133 or 137, respectively. In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising the following first and second polynucleotides: (a) the first and second polynucleotides comprising SEQ ID NOs. 139 and 145, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of either SEQ ID NOs. (b) a first vector or lipoplex (e.g., LNP) containing a single polynucleotide; (b) a second vector or lipoplex (e.g., LNP) containing a first and second polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of the polynucleotides containing SEQ ID NOs. 143 and 149, or SEQ ID NOs. 139 and 145.In some embodiments, the kit comprises first, second, third, and fourth viral vectors or lipoplexes (e.g., LNPs), each vector or lipoplex (e.g., LNP) comprising first and second polynucleotides: (a) first and second polynucleotides comprising SEQ ID NOs. 131 and 135, or one of SEQ ID NOs. 131 and 135, each comprising at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, and 92%. (b) A first viral vector or lipoplex (e.g., LNP) containing a polynucleotide that is identical to %, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively; (b) A first and second polynucleotide containing SEQ ID NOs. 133 and 137, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or less of either SEQ ID NOs. 133 and 137. (c) A second viral vector or lipoplex (e.g., LNP) containing a polynucleotide that is 99% identical to the first and second polynucleotides, including SEQ ID NOs. 139 and 145, or a third polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 139 or 145. (d) a viral vector or lipoplex (e.g., LNP), (d) a first and second polynucleotide comprising SEQ ID NOs. 142 and 148, or a fourth viral vector or lipoplex (e.g., LNP) which is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 142 or 148.In some embodiments, the kit comprises a first and a second viral vector or lipoplex (e.g., LNP) comprising the following first and second polynucleotides: (a) the first and second polynucleotides comprising SEQ ID NOs. 140 and 146, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of either SEQ ID NOs. 140 and 146, respectively. (b) a first vector or lipoplex (e.g., LNP) comprising a single polynucleotide; (b) a second vector or lipoplex (e.g., LNP) comprising a first and second polynucleotide comprising SEQ ID NOs. 143 and 149, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 143 and 149, respectively. In some embodiments, the first and second viral vectors are lymphocytic choriomeningitis mammalenavirus (LCMV) viral vectors.In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising the following first and second polynucleotides: (a) the first and second polynucleotides comprising polynucleotides including SEQ ID NOs. 150 and 152, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 150 or 152, respectively. (b) a first vector or lipoplex (e.g., LNP), (a) a second vector or lipoplex (e.g., LNP) comprising the first and second polynucleotides including SEQ ID NOs: 154 and 157 or SEQ ID NOs: 155 and 158, or a second vector or lipoplex (e.g., LNP) which is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 154 and 157 or SEQ ID NOs: 155 and 158, respectively. In some embodiments, the first and second viral vectors are Kalimanmalenavirus (also known as Pitchin de Mammamalenavirus or Pitchin de Arenavirus) viral vectors.In some embodiments, the kit comprises first, second, third, and fourth viral vectors or lipoplexes (e.g., LNPs), each vector or lipoplex (e.g., LNP) comprising first and second polynucleotides: (a) first and second polynucleotides comprising SEQ ID NOs. 140 and 146, or one of SEQ ID NOs. 140 and 146, each comprising at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, and 94%. (b) A first viral vector or lipoplex (e.g., LNP) containing a polynucleotide that is identical by %, 95%, 96%, 97%, 98%, or 99%, respectively; (b) First and second polynucleotides containing SEQ ID NOs. 143 and 149, or polynucleotides that are identical by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively. (c) a second viral vector or lipoplex (e.g., LNP) containing otidol, (c) a third viral vector or lipoplex (e.g., LN) containing the first and second polynucleotides comprising SEQ ID NOs. 150 and 152, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 150 or 152. P), (d) a fourth viral vector or lipoplex (e.g., LNP) comprising the first and second polynucleotides comprising SEQ ID NOs: 154 and 157 or SEQ ID NOs: 155 and 158, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 154 and 157 or SEQ ID NOs: 155 and 158, respectively.In some embodiments, the kit comprises first, second, third, and fourth viral vectors or lipoplexes (e.g., LNPs), each vector or lipoplex (e.g., LNP) comprising first and second polynucleotides: (a) first and second polynucleotides comprising SEQ ID NOs. 150 and 152, or one of SEQ ID NOs. 150 and 152, with at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, and 92% respectively. (b) A first viral vector or lipoplex (e.g., LNP) containing a polynucleotide that is identical to %, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively; (b) A first and second polynucleotide containing SEQ ID NOs. 155 and 158, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or less of either SEQ ID NOs. 155 and 158. (c) A second viral vector or lipoplex (e.g., LNP) containing a polynucleotide that is 99% identical to the first and second polynucleotides, including SEQ ID NOs. 151 and 153, or a third polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 151 or 153. (d) a viral vector or lipoplex (e.g., LNP), (d) a first and second polynucleotide comprising SEQ ID NOs. 156 and 159, or a fourth viral vector or lipoplex (e.g., LNP) which is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs. 156 and 159. In various embodiments, one or more of the first, second, third, and fourth vectors are adenovirus vectors.In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising the following first and second polynucleotides: (a) the first and second polynucleotides comprising SEQ ID NOs. 160 and 161, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of either SEQ ID NOs. 160 and 161, respectively. (b) a first vector or lipoplex (e.g., LNP) comprising a single polynucleotide; (b) a second vector or lipoplex (e.g., LNP) comprising a first and a second polynucleotide comprising SEQ ID NOs. 162 and 163, or each polynucleotide being at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 162 or 163. In some embodiments, the kit comprises first and second viral vectors, each containing the following first and second polynucleotides: (a) the first and second polynucleotides, each containing at least 80%, 81%, 82%, 83%, 84%, 85%, and 86% of either one of the first and second polynucleotides containing sequence numbers 164 and 165. (b) a first vector or lipoplex (e.g., LNP) comprising a polynucleotide that is identical to, (b) a first and second polynucleotide comprising SEQ ID NOs. 166 and 167, or each of SEQ ID NOs. 166 and 167, by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%. In some embodiments, the kit includes (a) a first viral vector or lipoplex (e.g.,) comprising a first polynucleotide containing SEQ ID NO: 210, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 210. (b) a second viral vector or lipoplex (e.g., LNP) comprising a polynucleotide containing the sequence number 211, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the sequence number 211.In some embodiments, the kit includes (a) a first viral vector or lipoplex (e.g.) comprising a first polynucleotide containing SEQ ID NO: 212, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 212. (b) a second viral vector or lipoplex (e.g., LNP) comprising a polynucleotide containing SEQ ID NO: 213, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 213. In some embodiments, the kit includes (a) a first viral vector or lipoplex (e.g.,) comprising a first polynucleotide containing SEQ ID NO: 214, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 214. (b) a second viral vector or lipoplex (e.g., LNP) comprising a polynucleotide containing the sequence number 215, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the sequence number 215.In some embodiments, the kit comprises (a) a first viral vector or lipoplex (e.g.) containing a first polynucleotide comprising SEQ ID NO: 216, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 216. (b) a second viral vector or lipoplex (e.g., LNP) comprising a polynucleotide containing SEQ ID NO: 217, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 217. In some embodiments, the kit comprises (a) a first viral vector or lipoplex (e.g.) containing a first polynucleotide comprising SEQ ID NO: 218, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 218. (b) a second viral vector or lipoplex (e.g., LNP) comprising a polynucleotide containing the sequence number 219, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the sequence number 219.In some embodiments, the kit comprises (a) a first viral vector or lipoplex (e.g.) containing a first polynucleotide comprising SEQ ID NO: 218, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 218. (b) a second viral vector or lipoplex (e.g., LNP) comprising a polynucleotide containing the sequence number 226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the sequence number 226. In some embodiments, the kit comprises (a) a first viral vector or lipoplex (e.g.) containing a first polynucleotide comprising SEQ ID NO: 225, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 225. (b) a second viral vector or lipoplex (e.g., LNP) comprising a polynucleotide containing the sequence number 226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the sequence number 226.In some embodiments, the kit comprises a complex fusion polypeptide and a vector or lipoplex (e.g., LNP) containing a polynucleotide encoding the complex fusion polypeptide, wherein the complex fusion polypeptide contains, or comprises, an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of the sequences 105-112, 200-209, 222-223, and 227. In some embodiments, the kit comprises a complex fusion polypeptide and a vector or lipoplex (e.g., LNP) containing a polynucleotide encoding the complex fusion polypeptide, wherein the complex fusion polypeptide contains, or comprises, an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 209, 222, and 223. In some embodiments, one or more fusion polypeptides include Gag 54-146, Gag. It does not include 370-500, Pol 1-55, Pol 118-128, Pol 321-366, Pol 432-541, Pol 607-682, Pol 709-746, Pol 828-839, Pol 921-931, Nef 1-63, Nef 100-116 and Nef 149-206, or any polypeptide segments corresponding to these fragments or subsequences, where the amino acid positions of Gag, Pol and Nef correspond to SEQ ID NOs. 1, 2 and 3, respectively. In some embodiments, one or more fusion polypeptides do not contain polypeptide segments having amino acid sequences of SEQ ID NOs. 35-47, or fragments or subsequences thereof, or amino acid sequences that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs. 35-47, or fragments or subsequences thereof. In some embodiments, the kit further comprises one or more additional therapeutic agents in one or more unit doses. In some embodiments, the kit comprises one or more agents that activate latent HIV, for example, one or more latent infection reactivators (LRAs). In some embodiments, the kit comprises one or more LRAs selected from agonists or activators of one or more Toll-like receptors (TLRs), histone deacetylase (HDAC) inhibitors, proteasome inhibitors, protein kinase C (PKC) activators, Smyd2 inhibitors, BET-bromodomain 4 (BRD4) inhibitors, ionomycins, apoptosis protein inhibitor (IAP) antagonists, and second mitochondrial caspase activator (SMAC) mimics. In some embodiments, the kit comprises one or more agonists or activators of one or more Toll-like receptors (TLRs). In some embodiments, the TLR agonists or activators are selected from TLR2 agonists, TLR3 agonists, TLR4 agonists, TLR5 agonists, TLR7 agonists, TLR8 agonists, and TLR9 agonists.In some embodiments, the TLR7 agonist is selected from GS 9620 (besatrimod), R848 (reciquimod), DS-0509, LHC-165, and TMX-101 (imiquimod), and / or the TLR8 agonist is selected from GS-9688 (sergantrimod), R848 (reciquimod), and NKTR-262 (dual TLR7 / TLR8 agonist). In some embodiments, the kit includes one or more interleukin receptor agonists of interleukins selected from IL-2, IL-7, IL-12, and IL-15. In some embodiments, the kit includes one or more cytokines selected from IL-2, IL-7, IL-12, IL-15, and their variants. In some embodiments, the kit includes one or more innate immune activators. In some embodiments, one or more innate immune activators include agonists of receptors selected from fms-related tyrosine kinase 3 (FLT3), interferon gene stimulator (STING) receptor, DExD / H box helicase 58 (DDX58, also known as RIG-I), and nucleotide-binding oligomerized domain-containing 2 (NOD2). In some embodiments, the kit includes an agonist of fms-related tyrosine kinase 3 (FLT3). In some embodiments, the kit includes one or more antagonists or inhibitors of inhibitory immune checkpoint proteins or receptors, and / or one or more activators or agonists of stimulating immune checkpoint proteins or receptors. In some embodiments, one or more immune checkpoint proteins or receptors include CD27, CD70; CD40, CD40LG; CD47, CD48(S). LAMF2), transmembrane domain and immunoglobulin domain-containing 2 (TMIGD2, CD28H), CD84 (LY9B, SLAMF5), CD96, CD160, MS4A1 (CD20), CD244 (SLAMF4); CD276 (B7H3); V-set domain-containing T cell activation inhibitor 1 (VTCN1, B7H4); V-set immunomodulatory receptors (VSIR, B7H5, VISTA); immunoglobulin superfamily member 11 (IGSF11, VSIG3); natural killer cytotoxic receptor 3 ligand 1 (NCR3LG1, B7H6); HERV-H LTR-related 2 (HHLA2, B7H7); Inducible T cell costimulatory molecule (ICOS, CD278); Inducible T cell costimulatory molecule ligand (ICOSLG, B7H2); TNF receptor superfamily member 4 (TNFRSF4, OX40); TNF superfamily member 4 (TNFSF4, OX40L); TNFRSF8 (CD30), TNFSF8 (CD30L); TNFRSF10A (CD261, DR4, TRAILR1), TNFRSF9 (CD137), TNFSF9 (CD137L); TNFRSF10B (CD262, DR5, TRAILR2), TNFRSF10 (TRAIL); TNFRSF14 (HVEM, CD270), TNFSF14 (HVEML); CD272 (B and T lymphocyte-related (BTLA)); TNFRSF17 (BCMA, CD269), TNFSF13 B (BAFF); TNFRSF18 (GITR), TNFSF18 (GITRL); MHC class I polypeptide-related sequence A (MICA); MHC class I polypeptide-related sequence B (MICB); CD274 (CD274, PDL1, PD-L1); programmed cell death 1 (PDCD1, PD1, PD-1); cytotoxic T lymphocyte-related protein 4 (CTLA4, CD152); CD80 (B7-1), CD28; nectin cell adhesion molecule 2 (NECTIN2, CD112); CD226 (DNAM-1); poliovirus receptor (PVR) cell adhesion molecule (PVR, CD155); PVR-related immunoglobulin domain-containing (PVRIG, CD112R); T cell immune receptor with Ig and ITIM domains (TIGIT); T cell immunoglobulin and mucin domain-containing 4 (TIMD4; TIM4);Hepatitis A virus cell receptor 2 (HAVCR2, TIMD3, TIM3); Galectin 9 (LGALS9); Lymphocyte activation 3 (LAG3, CD223); Signal transduction lymphocyte activation molecule family member 1 (SLAMF1, SLAM, CD150); Lymphocyte antigen 9 (LY9, CD229, SLAMF3); SLAM family member 6 (SLAMF6, CD352); SLAM family member 7 (SLAMF7, CD319); UL16 binding Protein 1 (ULBP1); UL16-binding protein 2 (ULBP2); UL16-binding protein 3 (ULBP3); retinoic acid initial transcript 1E (RAET1E; ULBP4); retinoic acid initial transcript 1G (RAET1G; ULBP5); retinoic acid initial transcript 1L (RAET1L; ULBP6); lymphocyte activation 3 (CD223); killer cell immunoglobulin-like receptor, 3 Ig domains, and long cytoplasmic terminal 1 (KIR, CD158E1) Killer cell lectin-like receptor C1 (KLRC1, NKG2A, CD159A); Killer cell lectin-like receptor K1 (KLRK1, NKG2D, CD314); Killer cell lectin-like receptor C2 (KLRC2, CD159c, NKG2C); Killer cell lectin-like receptor C3 (KLRC3, NKG2E); Killer cell lectin-like receptor C4 (KLRC4, NKG2F); Killer cell immunoglobulin-like receptor, one Ig domain and a long cytoplasmic tail 2 (K The following are selected from IR2DL1); killer cell immunoglobulin-like receptor, 2 Ig domains and long cytoplasmic tail 2 (KIR2DL2); killer cell immunoglobulin-like receptor, 3 Ig domains and long cytoplasmic tail 2 (KIR2DL3); killer cell immunoglobulin-like receptor, 3 Ig domains and long cytoplasmic tail 1 (KIR3DL1); killer cell lectin-like receptor D1 (KLRD1); and SLAM family member 7 (SLAMF7). In some embodiments, the kit includes one or more blocking factors or inhibitors of one or more T cell inhibitory immune checkpoint proteins or receptors. In some embodiments, the T cell inhibitory immune checkpoint proteins or receptors are CD274 (CD274, PDL1, PD-L1); programmed cell death 1 ligand 2 (PDCD1LG2, PD-L2, CD273);Programmed cell death 1 (PDCD1, PD1, PD-1); cytotoxic T lymphocyte-associated protein 4 (CTLA4, CD152); CD276 (B7H3); V-set domain-containing T cell activation inhibitor 1 (VTCN1, B7H4); V-set immunomodulatory receptors (VSIR, B7H5, VISTA); immunoglobulin superfamily member 11 (IGSF11, VSIG3); TNFRSF14 (HVEM, CD270), TNFSF14 (HVEML); CD272 (B and T lymphocyte-associated (BTLA)); PVR-associated immunoglobulin domain-containing (PVRIG, CD112R); T cell immune receptor with Ig and ITIM domains (TIGIT); lymphocyte activation 3 (LAG 3; CD223); Hepatitis A virus cell receptor 2 (HAVCR2, TIMD3, TIM3); Galectin 9 (LGALS9); Killer cell immunoglobulin-like receptor, 3 Ig domains and long cytoplasmic end 1 (KIR, CD158E1); Killer cell immunoglobulin-like receptor, 1 Ig domain and long cytoplasmic tail 2 (KIR2DL1); Killer cell immunoglobulin-like receptor, 2 Ig domains and long cytoplasmic tail 2 (KIR2DL2); Killer cell immunoglobulin-like receptor, 3 Ig domains and long cytoplasmic tail 2 (KIR2DL3); and Killer cell immunoglobulin-like receptor, 3 Ig domains and long cytoplasmic tail 1 (KIR3DL1). In some embodiments, the kit comprises one or more agonists or activators of one or more T cell-stimulating immune checkpoint proteins or receptors. In some embodiments, the T cell-stimulating immune checkpoint protein or receptor is CD27, CD70; CD40, CD40LG; inducible T cell costimulatory molecule (ICOS, CD278); inducible T cell costimulatory molecule ligand (ICOSLG, B7H2); TNF receptor superfamily member 4 (TNFRSF4, OX40); TNF superfamily member 4 (TNFSF4, OX40L); TNFRSF9 (CD137), TNFSF9 (CD137L); TNFRSF18 (GITR), TNFSF18 (GITRL); CD80 (B7-1), CD28; nectin cell adhesion molecule 2 (NECTIN2, CD112); CD226 (DNAM-1);The kit is selected from poliovirus receptor (PVR) cell adhesion molecules (PVR, CD155). In some embodiments, the kit further comprises one or more NK cell inhibitory immune checkpoint proteins or receptors, one or more blocking factors or inhibitors. In some embodiments, the NK cell inhibitory immune checkpoint protein or receptor is selected from killer cell immunoglobulin-like receptor, 3 Ig domains, and long cytoplasmic end 1 (KIR, CD158E1); killer cell immunoglobulin-like receptor, 1 Ig domain, and long cytoplasmic tail 2 (KIR2DL1); killer cell immunoglobulin-like receptor, 2 Ig domains, and long cytoplasmic tail 2 (KIR2DL2); killer cell immunoglobulin-like receptor, 3 Ig domains, and long cytoplasmic tail 2 (KIR2DL3); killer cell immunoglobulin-like receptor, 3 Ig domains, and long cytoplasmic tail 1 (KIR3DL1); killer cell lectin-like receptor C1 (KLRC1, NKG2A, CD159A); and killer cell lectin-like receptor D1 (KLRD1, CD94). In some embodiments, the kit comprises one or more agonists or activators of one or more NK cell stimulating immune checkpoint proteins or receptors. In some embodiments, the NK cell-stimulated immune checkpoint proteins or receptors are CD16, CD226 (DNAM-1); killer cell lectin-like receptor K1 (KLRK1, NKG2D, CD314);And selected from SLAM family member 7 (SLAMF7). In some embodiments, one or more immune checkpoint inhibitors include protein inhibitors of PD-L1 (CD274), PD-1 (PDCD1), or CTLA4. In some embodiments, the kit includes an antibody that binds to CTLA4. In some embodiments, the protein or antibody inhibitor of CTLA4 is ipilimumab, tremelimumab, BMS-986218, AGEN1181, AGEN1884, BMS-986249, MK-1308, REGN-4659, ADU-1604, CS-1002, BCD-145, APL-509, JS-007, BA-3071, ONC-392, AGEN-2041, JHL-1155, KN-044, C G-0161, ATOR-1144, PBI-5D3H5, FPT-155(CTLA4 / PD-L1 / CD28), PF-06936308(PD-1 / CTLA4), MGD-019(PD-1 / CTLA 4), KN-046 (PD-1 / CTLA4), MEDI-5752 (CTLA4 / PD-1), XmAb-20717 (PD-1 / CTLA4), and AK-104 (CTLA4 / PD-1). In some embodiments, the protein inhibitors of PD-L1 (CD274) or PD-1 (PDCD1) include pembrolizumab, nivolumab, semiprimab, pidilizumab, AMP-224, MEDI0680 (AMP-514), spartalizumab, atezolizumab, avelumab, durvalumab, BMS-936559, CK-301, PF-06801591, BGB-A317 (tislerizumab), GLS-010 (WBP-3055), AK-103 (HX-008), AK-105, CS-1003, and HLX-1. 0, MGA-012, BI-754091, AGEN-2034, JS-001 (tripalimab), JNJ-63723283, genolimuzumab (CBT-501), LZM-009, BCD-100, LY-3300054, SHR-1201, SHR-1210 (camrelizumab), Sym-021, ABBV-181, PD1-PIK, BAT-1306, (MSB0010718C), CX-072, CBT-502, TSR-042 (dostarlimab), MS; B-2311, JTX-4014, BGB-A333, SHR-1316, CS-1001 (WBP-3155, KN-035, IBI-308 Mab), HLX-20, KL-A167, STI-A1014, STI-A1015(IMC-001), BCD-135, FAZ-053, TQB-24 50, MDX1105-01, FPT-155 (CTLA4 / PD-L1 / CD28), PF-06936308 (PD-1 / CTLA4), MGD-01 3(PD-1 / LAG-3), FS-118(LAG-3 / PD-L1)MGD-019(PD-1 / CTLA4), KN-046(PD-1 / CTLA4 ), MEDI-5752 (CTLA4 / PD-1), RO-7121661 (PD-1 / TIM-3), XmAb-20717 (PD-1 / CTLA4), AK-104 (CTLA4 / PD-1), M7824 (PD-L1 / TGFβ-EC domain), CA-170 (PD-L1 / VISTA), CDX-527 (CD27 / PD-L1), LY-3415244 (TIM3 / PDL1), and INBRX-105 (4-1BB / PDL1). In some embodiments, one or more immune checkpoint inhibitors are selected from CD274 (PDL1, PD-L1), programmed cell death 1 (PDCD1, PD1, PD-1 The kit includes a small molecule inhibitor of ), or CTLA4. In some embodiments, the small molecule inhibitor of CD274 or PDCD1 is selected from GS-4224, GS-4416, INCB086550, and MAX10181. In some embodiments, the small molecule inhibitor of CTLA4 includes BPI-002. In some embodiments, the kit further includes one or more antiviral agents. In some embodiments, one or more antiviral agents are selected from HIV protease inhibitors, HIV reverse transcriptase inhibitors, HIV integrase inhibitors, HIV non-catalytic (or allosteric) integrase inhibitors, HIV entry (fusion) inhibitors, HIV maturation inhibitors, and capsid inhibitors.

[0016] Methods for inducing an immune response to human immunodeficiency virus (HIV) in subjects requiring such induction include administering a fusion polypeptide, complex fusion polypeptide, polynucleotide, vector, lipoplex (e.g., LNP), or immunogenic composition described herein to the subject. Methods for treating or prophylacticizing human immunodeficiency virus (HIV) in subjects requiring such treatment include administering a fusion polypeptide, complex fusion polypeptide, vector, lipoplex (e.g., LNP), or immunogenic composition described herein to the subject. In some embodiments, the method involves administering a single vector comprising a first fusion polypeptide and one or more polynucleotides encoding a second fusion polypeptide. In some embodiments, two or more fusion polypeptides, two or more complex fusion polypeptides, two or more polynucleotides encoding a fusion polypeptide, two or more viral expression vectors comprising polynucleotides encoding a fusion polypeptide, two or more lipoplex (e.g., LNP), or two or more immunogenic compositions described herein are administered to the subject simultaneously or in parallel. In some embodiments, the two or more fusion polypeptides, or two or more polynucleotides encoding a fusion polypeptide, or two or more viral expression vectors are in the form of a bivalent antigen composition. In some embodiments, the method involves administering a first fusion polypeptide and a second fusion polypeptide, one or more polynucleotides encoding the first and second fusion polypeptides, one or more vectors comprising one or more polynucleotides encoding the first and second fusion polypeptides, or one or more lipoplexes (e.g., LNPs), wherein the first and second polypeptides comprise the following polypeptide segments optionally linked or connected by one or more linkers from the N-terminus to the C-terminus: SEQ ID NOs: 6, 4, 16, and 26, and SEQ ID NOs: 7, 5, 27, and 17, SEQ ID NOs: 12, 24, 8, and 10, and SEQ ID NOs: 9, 25, 13, and 11, SEQ ID NOs: 14, 22, 18, 24, and 20, and SEQ ID NOs: 15, 25, 19, 23, and 21, SEQ ID NOs: 26, 16, 4, and 6, and SEQ ID NOs: 7, 27, 5, and 17, SEQ ID NOs: 8, 24, 12,and 10, and sequence numbers 13, 25, 9, and 11, sequence numbers 22, 24, 14, 18, and 20, and sequence numbers 25, 23, 15, 21, and 19, sequence numbers 20, 6, 4, 18, 16, and 26, and sequence numbers 7, 19, 5, 21, 27, and 17, sequence numbers 8, 24, 14, 12, 22, and 10, and sequence numbers 9, 13, 25, 23, 15, and 11, sequence numbers 18, 26, 20, 4, 6, and 16, and sequence numbers 7, 21, 17, 5, 27, and 19, sequence numbers 22, 24, 12, 14, 8, and 10, and sequence numbers 15, 25, 9, 23, 13, and 11, SEQ ID NOs: 24, 6, 4, 20, 18, and 32, and SEQ ID NOs: 8, 30, 14, 12, 26, and 10, SEQ ID NOs: 24, 6, 4, 20, 18, and 32, and SEQ ID NOs: 7, 21, 5, 25, 33, and 19, SEQ ID NOs: 24, 6, 4, 20, 18, and 32, and SEQ ID NOs: 8, 30, 14, 12, 26, and 10, SEQ ID NOs: 8, 30, 14, 12, 26, and 10, and SEQ ID NOs: 9, 13, 31, 27, 15, and 11, SEQ ID NOs: 6, 20, 4, 24, 32, and 18, and SEQ ID NOs: 8, 12, 30, 26, 14, and 10, SEQ ID NOs: 7, 21, 5, 25, 33, and 19, and SEQ ID NOs: 9, 13, 31, 27, 15, and 11, SEQ ID NOs: 20, 32, 24, 4, 6, and 18, and SEQ ID NOs: 26, 30, 12, 14, 8, and 10, SEQ ID NOs: 7, 25, 19, 5, 33, and 21, and SEQ ID NOs: 15, 31, 9, 27, 13, and 11, SEQ ID NOs: 24, 6, 16, and 18, and SEQ ID NOs: 26, 20, 10, and 28, SEQ ID NOs: 24, 6, 16, and 18, and SEQ ID NOs: 26, 10, 20, and 28, SEQ ID NOs: 24, 6, 16, and 18, and SEQ ID NOs: 7, 25, 17, and 19, SEQ ID NOs: 7, 19, 17, and 25, and SEQ ID NOs: 21, 27, 11, and 29, SEQ ID NOs: 24, 16, 6, and 18, and SEQ ID NOs: 27, 11, 21, and 29, SEQ ID NOs: 7, 25, 17, and 19, and SEQ ID NOs: 11, 27, 21, and 29, SEQ ID NOs: 7, 25, 17, and 19, and SEQ ID NOs: 21, 27, 11, and 29, SEQ ID NOs: 22, 6, 20, and 28, and SEQ ID NOs: 23, 7, 21, and 29, SEQ ID NOs: 22, 20, 6, and 28, and SEQ ID NOs: 7, 21, 23, and 29, SEQ ID NOs: 26, 10, and 20,and 28, as well as sequence numbers 21, 27, 11, and 29, sequence numbers 22, 6, 16, 20, 18, 28, 26, and 10, or sequence numbers 7, 21, 19, 17, 27, 25, 29, and 11. In some embodiments, the method involves administering one or more fusion polypeptides, one or more polynucleotides encoding one or more fusion polypeptides, one or more vectors containing one or more polynucleotides encoding one or more fusion polypeptides, or one or more lipoplexes (e.g., LNPs), wherein one or more fusion polypeptides contain or consist of an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of the amino acid sequences of SEQ ID NOs. In some embodiments, the method involves administering one or more fusion polypeptides, one or more polynucleotides encoding one or more fusion polypeptides, one or more vectors containing one or more polynucleotides encoding one or more fusion polypeptides, or one or more lipoplexes (e.g., LNPs), wherein one or more fusion polypeptides contain or consist of an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of the sequences 82-83, 85-87, 98-101, 209, and 222-223. In some embodiments, the method comprises one or more polynucleotides, one or more vectors, or one or more lipoplexes (e.g.,) that encode the following first fusion polypeptide and second fusion polypeptide, and the following first fusion polypeptide and second fusion polypeptide optionally linked or connected by one or more linkers.The following are associated with the administration of LNPs: fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 70 and 71, or any one of SEQ ID NOs. 72 and 73, or any one of SEQ ID NOs. 72 and 73, or any one of SEQ ID NOs. 72 and 73, respectively, and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 9 Fusion polypeptides that are 3%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 74 and 75, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 76 and 77, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, or 86% identical to fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, or 86% identical to fusion polypeptides that are at least 86 Fusion polypeptides that are identical to %, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of Sequence ID No. 78 and 79, or fusion polypeptides that are identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of either80 and 81, or fusion polypeptides that are identical to at least one of Sequence ID No. 80 and 81 Fusion polypeptides that are 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to each other, SEQ ID NOs. 82 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to each other, SEQ ID NOs. 84 and 85,Or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 84 and 85, respectively, SEQ ID NOs. 86 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a fusion polypeptide, SEQ ID NOs. 82 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, or 958 and 89, or one of SEQ ID NOs. 88 and 89, respectively. , 96%, 97%, 98%, or 99% identical fusion polypeptide, SEQ ID NOs. 82 and 86, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical fusion polypeptide, SEQ ID NOs. 82 and 88, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 9 Fusion polypeptides that are 0%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 83 and 87, or each of SEQ ID NOs. 83 and 87, and each of them are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 85 and 87, or each of SEQ ID NOs. 85 and 87, and each of them are at least 80%, 81%, 82%, 83%, 84%,A fusion polypeptide that is 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 88 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87% identical to either SEQ ID NOs. 88 or 87, respectively. , fusion polypeptides identical to 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 84 and 88, or fusion polypeptides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 85 and 89, or fusion polypeptides identical to at least 80%, 81%, or 99%, one of SEQ ID NOs. 85 and 89, or fusion polypeptides identical to at least 80%, 81%, one of SEQ ID NOs. 85 and 89. , fusion polypeptides identical to 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 85 and 101, or fusion polypeptides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 90 and 91, or SEQ ID NOs. 90 and 9 A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of the above, SEQ ID NOs. 92 and 93, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of the above, , fusion polypeptides identical to, at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of, fusion polypeptides identical to, respectively, sequence numbers 96 and 97, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,Fusion polypeptides that are 98% or 99% identical to SEQ ID NOs. 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 9 A fusion polypeptide that is 0%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 220 and 221, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 98 and 100, or a fusion polypeptide that is at least 80%, 8% identical to either SEQ ID NOs. 98 and 100. Fusion polypeptides identical to 1%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 99 and 101, or fusion polypeptides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 98 and 99, or A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 100 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, or 97%, respectively.A fusion polypeptide that is 98% or 99% identical. In some embodiments, the method involves administering one or more vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first and second fusion polypeptides, which are optionally linked or connected from the N-terminus to the C-terminus by one or more linkers: at least 80%, 81%, 82%, 83%, 84%, 85% of either SEQ ID NOs. 70 and 71, or one of SEQ ID NOs. 70 and 71, respectively. Fusion polypeptides that are 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 71 and 70, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 72 and 73 Fusion polypeptides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 73 and 72, or fusion polypeptides identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively, SEQ ID NOs. 7 A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either 4 and 75, or either one of 74 and 75, respectively; fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,Fusion polypeptides that are 98% or 99% identical to SEQ ID NOs. 76 and 77, or any one of SEQ ID NOs. 76 and 77, and each of them are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 77 and 76, or any one of SEQ ID NOs. 77 and 76, and each of them are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91% identical to SEQ ID NOs. A fusion polypeptide that is identical to %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of SEQ ID NOs. 78 and 79, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of either SEQ ID NOs. 79 and 78, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, 84%, or 8 A fusion polypeptide that is 5%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 80 and 81, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 81 and 8097%, 98%, or 99% identical to either SEQ ID NOs. 81 and 80 Fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical, SEQ ID NOs. 82 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 82 or 83, respectively, SEQ ID NOs. 83 and 82,Or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 83 and 82, respectively, SEQ ID NOs. 84 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a fusion polypeptide, SEQ ID NOs. 85 and 84, or one of SEQ ID NOs. 86 and 87, or one of SEQ ID NOs. 86 and 87, or one of SEQ ID NOs. 86 and 87, are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, or 95% identical to a fusion polypeptide, SEQ ID NOs. 85 and 845 and 84, respectively. , 96%, 97%, 98%, or 99% identical fusion polypeptide, SEQ ID NOs. 87 and 86, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical fusion polypeptide, SEQ ID NOs. 88 and 89, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 9 Fusion polypeptides that are 0%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical, SEQ ID NOs. 89 and 88, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 82 and 85, or at least 80%, 81%, 82%, 83%, 84%, respectively.A fusion polypeptide that is 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 85 and 82, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 9, Fusion polypeptides that are 5%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 86 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, or 89% identical to either SEQ ID NOs. 86 and 82, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, or 89% identical to either SEQ ID NOs. A fusion polypeptide that is identical to %, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 82 and 88, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, SEQ ID NOs. 88 and 82, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%,90%, 81%, 82%, 83%, or a fusion polypeptide that is identical to at least 90%, 81%, 82%, 83%, or a fusion polypeptide that is identical to at least 90%, 81%, 82%, 83%, or a fusion polypeptide that is identical to at least 90%, 81%, 82%, 83%, or a fusion polypeptide that is identical to at least 90%, A fusion polypeptide that is 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 83 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 83 and 83, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 87 and 83, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. Fusion polypeptides, SEQ ID NOs. 85 and 87, which are identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of each, respectively; or fusion polypeptides, SEQ ID NOs. 87 and 85, which are identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of each, respectively;Or a fusion polypeptide identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of either SEQ ID NOs. 87 and 88, or identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of either SEQ ID NOs. 88 and 87, or identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of either SEQ ID NOs. A fusion polypeptide that is identical to SEQ ID NOs. 87 and 88, or one of SEQ ID NOs. 87 and 88, by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively, a fusion polypeptide that is identical to SEQ ID NOs. 84 and 88, or one of SEQ ID NOs. 88 and 84, by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, or 95%. A fusion polypeptide that is identical to %, 96%, 97%, 98%, or 99% of Sequence ID No. 88 and 84, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of Sequence ID No. 85 and 89, or a fusion polypeptide that is identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, or 89% of Sequence ID No. 85 and 89, A fusion polypeptide that is 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 89 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 85 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, or 99% identical to either SEQ ID NOs. 85 and 101,A fusion polypeptide that is 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 101 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 90 and 91 Fusion polypeptides, SEQ ID NOs. 91 and 90, which are identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% respectively, SEQ ID NOs. 91 and 90, or fusion polypeptides, SEQ ID NOs. 92 and 90, which are identical to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% respectively, SEQ ID NOs. 92 and 90 3. A fusion polypeptide which is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 92 and 93, respectively; or a fusion polypeptide which is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NOs. 93 and 92, respectively. A fusion polypeptide that is identical to SEQ ID NOs. 94 and 95, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 95 and 94, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%,Fusion polypeptides that are 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 96 and 97, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs. 97 and 96, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, respectively. Fusion polypep...

Claims

1. A fusion polypeptide comprising, or consisting of, one amino acid sequence of any one of SEQ ID NOs. 94 to 101, or an amino acid sequence that is at least 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to one of SEQ ID NOs. 94 to 101, wherein the total length of the fusion polypeptide is 505 amino acids or less, and the fusion polypeptide is, a) Sequence segments that are at least 90% identical to sequence numbers 4, 6, 18, 20, 24, and 32, b) Sequence segments that are at least 90% identical to sequence numbers 5, 7, 19, 21, 25, and 33, c) Sequence segments that are at least 90% identical to sequence numbers 8, 10, 12, 14, 26, and 30, or d) A sequence segment that is at least 90% identical to sequence numbers 9, 11, 13, 15, 27, and 31, The fusion polypeptide is capable of inducing, promoting, or stimulating the proliferation and / or activation of one or more cell types selected from monocyte-derived dendritic cells (DCs), CD8+ T cells, and CD4+ T cells in humans.

2. The fusion polypeptide according to claim 1, further comprising an N-terminal signal peptide or a leader sequence.

3. The fusion polypeptide according to claim 1 or 2, wherein the fusion polypeptide can induce, promote, or stimulate an immune response to HIV-1 in humans.

4. The fusion polypeptide according to any one of claims 1 to 3, wherein the fusion polypeptide can induce, promote, or stimulate the proliferation and / or activation of CD8+ T cells in humans.

5. A polynucleotide comprising a nucleic acid sequence encoding one or more fusion polypeptides according to any one of claims 1 to 4.

6. The polynucleotide according to claim 5, which encodes the fusion polypeptide according to claim 1, comprising one nucleic acid sequence from sequence numbers 130 to 149, or a nucleic acid sequence that is at least 90% identical to one of sequence numbers 130 to 149.

7. An expression cassette comprising a polynucleotide according to any one of claims 5 to 6, which is operably linked to one or more regulatory sequences.

8. A vector comprising one or more polynucleotides according to any one of claims 5 to 6, or comprising an expression cassette according to claim 7.

9. A vector according to claim 8, comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, wherein the first fusion polypeptide comprises the amino acid sequence of SEQ ID NO: 98, and the second fusion polypeptide comprises the amino acid sequence of SEQ ID NO: 100, or each is a fusion polypeptide that is at least 93% identical to either SEQ ID NO: 98 or 100.

10. A vector according to claim 8, comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, wherein the first fusion polypeptide comprises the amino acid sequence of SEQ ID NO: 99, and the second fusion polypeptide comprises the amino acid sequence of SEQ ID NO: 101, or each is a fusion polypeptide that is at least 93% identical to either SEQ ID NO: 99 or 101.

11. The following are the first and second polynucleotides: a) A first polynucleotide containing SEQ ID NO: 140, or a polynucleotide that is at least 90% identical to SEQ ID NO: 140, and b) A second polynucleotide containing the polynucleotide of sequence number 146, or a polynucleotide that is at least 90% identical to sequence number 146. The vector according to claim 9, including the vector described in claim 9.

12. The following are the first and second polynucleotides: a) A first polynucleotide containing SEQ ID NO: 143, or a polynucleotide that is at least 90% identical to SEQ ID NO: 143, and b) A second polynucleotide containing SEQ ID NO: 149, or a polynucleotide that is at least 90% identical to SEQ ID NO:

149. The vector according to claim 10, including

13. The vector according to any one of claims 8 to 12, wherein the vector is a viral vector.

14. The vector according to claim 13, wherein the viral vector is replication-deficient, replication-deleted, replication-attenuated, or replication-capable.

15. The vector according to claim 13 or claim 14, wherein the viral vector is an arenavirus vector selected from lymphocytic choriomeningitis mammalenavirus (LCMV), Kali mammalenavirus (also known as pitin de mammalenavirus or pitin de arenavirus), guanalitovirus (GTOV), Junin virus (JUNV), Lassa virus (LASV), Lujo virus (LUJV), Macpo virus (MACV), Sabia virus (SABV), and Whitewater Arroyo virus (WWAV).

16. The vector according to claim 15, wherein the viral vector is an arenavirus vector selected from lymphocytic choriomeningitis mammalenavirus (LCMV) or Kali mammalenavirus (also known as pitin de mammalenavirus or pitin de arenavirus).

17. The vector according to any one of claims 15 to 16, wherein the arenavirus vector comprises a three-segmented genome.

18. A host cell comprising one or more polynucleotides according to any one of claims 5 to 6, or one or more vectors according to any one of claims 8 to 17, wherein the host cell is a host cell excluding human cells obtained by introducing one or more polynucleotides or one or more vectors into a human in vivo.

19. An immunogenic composition comprising two or more fusion polypeptides according to any one of claims 1 to 4, or two or more polynucleotides according to any one of claims 5 to 6, or two or more vectors according to any one of claims 8 to 17, and a pharmaceutically acceptable carrier.

20. First and second viral vectors comprising one or more polynucleotides encoding the following first and second fusion polypeptides: a) A first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide comprising the amino acid sequence of SEQ ID NO: 98, or an amino acid sequence identical to at least 93% of SEQ ID NO: 98, and a second fusion polypeptide comprising the amino acid sequence of SEQ ID NO: 100, or an amino acid sequence identical to at least 93% of SEQ ID NO: 100, and b) A second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide comprising the amino acid sequence of SEQ ID NO: 99, or an amino acid sequence identical to at least 93% of SEQ ID NO: 99, and a second fusion polypeptide comprising the amino acid sequence of SEQ ID NO: 101, or an amino acid sequence identical to at least 93% of SEQ ID NO:

101. The immunogenic composition according to claim 19, comprising:

21. First and second viral vectors comprising the following first and second polynucleotides: a) A first vector comprising a first and a second polynucleotide, wherein (i) the first polynucleotide comprises the nucleic acid sequence of SEQ ID NO: 139, or a nucleic acid sequence that is at least 90% identical to SEQ ID NO: 139, and the second polynucleotide comprises the nucleic acid sequence of SEQ ID NO: 145, or a nucleic acid sequence that is at least 90% identical to SEQ ID NO: 145, or (ii) the first polynucleotide comprises the nucleic acid sequence of SEQ ID NO: 140, or a nucleic acid sequence that is at least 90% identical to SEQ ID NO: 140, and the second polynucleotide comprises the nucleic acid sequence of SEQ ID NO: 146, or a nucleic acid sequence that is at least 90% identical to SEQ ID NO: 146, and b) A second vector comprising a first and a second polynucleotide, wherein (i) the first polynucleotide comprises the nucleic acid sequence of SEQ ID NO: 142, or a nucleic acid sequence that is at least 90% identical to SEQ ID NO: 142, and the second polynucleotide comprises the nucleic acid sequence of SEQ ID NO: 148, or a nucleic acid sequence that is at least 90% identical to SEQ ID NO: 148, or (ii) the first polynucleotide comprises the nucleic acid sequence of SEQ ID NO: 143, or a nucleic acid sequence that is at least 90% identical to SEQ ID NO: 143, and the second polynucleotide comprises the nucleic acid sequence of SEQ ID NO: 149, or a nucleic acid sequence that is at least 90% identical to SEQ ID NO:

149. The immunogenic composition according to claim 19, comprising:

22. The immunogenic composition according to claim 20 or 21, wherein the first and second viral vectors are lymphocytic choriomeningitis mammalenavirus (LCMV) viral vectors.

23. The immunogenic composition according to claim 20 or 21, wherein the first and second viral vectors are Kalimanmalenavirus (also known as pitin de mammalenavirus or pitin de arenavirus) viral vectors.

24. An immunogenic composition according to any one of claims 19 to 23, formulated for administration via a route selected from intravenous, intramuscular, intradermal, subcutaneous, intranodal, and intramucosal (e.g., cheek, nasal cavity, rectal, vaginal).

25. An immunogenic composition according to any one of claims 19 to 24, formulated as a liquid, suspension, or emulsion.

26. The immunogenic composition according to any one of claims 19 to 24, wherein the composition is freeze-dried.

27. A kit comprising one or more unit doses of one or more fusion polypeptides according to any one of claims 1 to 4, one or more polynucleotides according to any one of claims 5 to 6, one or more vectors according to any one of claims 8 to 17, or one or more immunogenic compositions according to any one of claims 19 to 26.

28. The kit according to claim 27, comprising one or more containers selected from vials, ampoules, and pre-filled syringes.

29. An immunogenic composition according to any one of claims 19 to 26 for treating or preventing human immunodeficiency virus (HIV) in a target population where it is needed.

30. First and second viral vectors comprising one or more polynucleotides encoding the following first and second fusion polypeptides: a) A first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide comprising the amino acid sequence of SEQ ID NO: 98, or an amino acid sequence identical to at least 93% of SEQ ID NO: 98, and a second fusion polypeptide comprising the amino acid sequence of SEQ ID NO: 100, or an amino acid sequence identical to at least 93% of SEQ ID NO: 100, and b) A second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide comprising the amino acid sequence of SEQ ID NO: 99, or an amino acid sequence identical to at least 93% of SEQ ID NO: 99, and a second fusion polypeptide comprising the amino acid sequence of SEQ ID NO: 101, or an amino acid sequence identical to at least 93% of SEQ ID NO:

101. The immunogenic composition according to claim 29, comprising:

31. The immunogenic composition according to claim 30, wherein the first and second viral vectors are lymphocytic choriomeningitis mammalenavirus (LCMV) viral vectors.

32. The immunogenic composition according to claim 30, wherein the first and second viral vectors are Kalimanmalenavirus (also known as pitin de mammalenavirus or pitin de arenavirus) viral vectors.

33. First and second viral vectors comprising the following first and second polynucleotides: a) A first vector comprising a first and a second polynucleotide, wherein (i) the first polynucleotide comprises the nucleic acid sequence of SEQ ID NO: 139, or a nucleic acid sequence identical to SEQ ID NO: 139 by at least 93%, and the second polynucleotide comprises the nucleic acid sequence of SEQ ID NO: 145, or a nucleic acid sequence identical to SEQ ID NO: 145 by at least 90%, or (ii) the first polynucleotide comprises the nucleic acid sequence of SEQ ID NO: 140, or a nucleic acid sequence identical to SEQ ID NO: 140 by at least 90%, and the second polynucleotide comprises the nucleic acid sequence of SEQ ID NO: 146, or a nucleic acid sequence identical to SEQ ID NO: 146 by at least 90%, and b) A second vector comprising a first and a second polynucleotide, wherein (i) the first polynucleotide comprises the nucleic acid sequence of SEQ ID NO: 142, or a nucleic acid sequence that is at least 90% identical to SEQ ID NO: 142, and the second polynucleotide comprises the nucleic acid sequence of SEQ ID NO: 148, or a nucleic acid sequence that is at least 90% identical to SEQ ID NO: 148, or (ii) the first polynucleotide comprises the nucleic acid sequence of SEQ ID NO: 143, or a nucleic acid sequence that is at least 90% identical to SEQ ID NO: 143, and the second polynucleotide comprises the nucleic acid sequence of SEQ ID NO: 149, or a nucleic acid sequence that is at least 90% identical to SEQ ID NO:

149. An immunogenic composition according to claim 29, comprising the first and second viral vectors being Kalimanmalenavirus (also known as pitin de mammalenavirus or pitin de arenavirus) viral vectors.

34. The subject is an immunogenic composition according to any one of claims 29 to 33, wherein the subject is infected with HIV-1, suspected of being infected with HIV-1, or at risk of becoming infected with HIV-1.

35. The immunogenic composition according to any one of claims 29 to 34, wherein the fusion polypeptide, the polynucleotide, the vector, or the immunogenic composition is administered via a route selected from intravenous, intramuscular, intradermal, subcutaneous, intranodal, and intramucosal.

36. Approximately 10 per dose ３ ~about 10 １２ An immunogenic composition according to any one of claims 29 to 35, characterized by administering viral focus-forming units (FFUs), plaque-forming units (PFUs), infection units (IUs), or viral particles (VPs).

37. An immunogenic composition according to any one of claims 29 to 36 for use in a method comprising a prime-boost regimen, which includes administering a priming composition at a first time point and administering one or more boosting compositions at one or more time points thereafter.

38. The aforementioned Prime-Boost Resimen, 1) First and second viral vectors comprising one or more polynucleotides encoding the following first and second fusion polypeptides, linked or connected by one or more linkers: a) A first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide comprising the amino acid sequence of SEQ ID NO: 82 or an amino acid sequence identical to at least 90% of SEQ ID NO: 82, and a second fusion polypeptide comprising the amino acid sequence of SEQ ID NO: 86 or an amino acid sequence identical to at least 90% of SEQ ID NO: 86; and b) A second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide comprising the amino acid sequence of SEQ ID NO: 83 or an amino acid sequence that is at least 90% identical to SEQ ID NO: 83, and a second fusion polypeptide comprising the amino acid sequence of SEQ ID NO: 87 or an amino acid sequence that is at least 90% identical to SEQ ID NO:

87. Priming with an immunogenic composition containing; 2) Third and fourth viral vectors comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: a) A third viral vector comprising one or more polynucleotides encoding a first fusion polypeptide comprising the amino acid sequence of SEQ ID NO: 98 or an amino acid sequence identical to at least 93% of SEQ ID NO: 98, and a second fusion polypeptide comprising the amino acid sequence of SEQ ID NO: 100 or an amino acid sequence identical to at least 93% of SEQ ID NO: 100; and b) A fourth viral vector comprising one or more polynucleotides encoding a first fusion polypeptide comprising the amino acid sequence of SEQ ID NO: 99 or an amino acid sequence identical to SEQ ID NO: 99 by at least 93%, and a second fusion polypeptide comprising the amino acid sequence of SEQ ID NO: 101 or an amino acid sequence identical to SEQ ID NO: 101 by at least 93%. Boosting with an immunogenic composition containing The immunogenic composition according to claim 37, comprising:

39. The aforementioned Prime-Boost Resimen, 1) First and second viral vectors containing the following polynucleotides: a) A first viral vector comprising a first and a second polynucleotide, wherein the first polynucleotide comprises the nucleic acid sequence of SEQ ID NO: 150 or a nucleic acid sequence that is at least 90% identical to SEQ ID NO: 150, and the second polynucleotide comprises the nucleic acid sequence of SEQ ID NO: 152 or a nucleic acid sequence that is at least 90% identical to SEQ ID NO: 152; and b) A second viral vector comprising a first and a second polynucleotide, wherein (i) the first polynucleotide comprises the nucleic acid sequence of SEQ ID NO: 155, or a nucleic acid sequence that is at least 90% identical to SEQ ID NO: 155, and the second polynucleotide comprises the nucleic acid sequence of SEQ ID NO: 158, or a nucleic acid sequence that is at least 90% identical to SEQ ID NO: 158, or (ii) the first polynucleotide comprises the nucleic acid sequence of SEQ ID NO: 154, or a nucleic acid sequence that is at least 90% identical to SEQ ID NO: 154, and the second polynucleotide comprises the nucleic acid sequence of SEQ ID NO: 157, or a nucleic acid sequence that is at least 90% identical to SEQ ID NO:

157. Priming with an immunogenic composition containing; 2) Third and fourth viral vectors containing the following polynucleotides: a) A third viral vector comprising first and second polynucleotides, wherein (i) the first polynucleotide comprises the nucleic acid sequence of SEQ ID NO: 139, or a nucleic acid sequence that is at least 90% identical to SEQ ID NO: 139, and the second polynucleotide comprises the nucleic acid sequence of SEQ ID NO: 145, or a nucleic acid sequence that is at least 90% identical to SEQ ID NO: 145, or (ii) the first polynucleotide comprises the nucleic acid sequence of SEQ ID NO: 140, or a nucleic acid sequence that is at least 90% identical to SEQ ID NO: 140, and the second polynucleotide comprises the nucleic acid sequence of SEQ ID NO: 146, or a nucleic acid sequence that is at least 90% identical to SEQ ID NO: 146; and b) A fourth viral vector comprising first and second polynucleotides, wherein (i) the first polynucleotide comprises the nucleic acid sequence of SEQ ID NO: 142, or a nucleic acid sequence that is at least 90% identical to SEQ ID NO: 142, and the second polynucleotide comprises the nucleic acid sequence of SEQ ID NO: 148, or a nucleic acid sequence that is at least 90% identical to SEQ ID NO: 148, or (ii) the first polynucleotide comprises the nucleic acid sequence of SEQ ID NO: 143, or a nucleic acid sequence that is at least 90% identical to SEQ ID NO: 143, and the second polynucleotide comprises the nucleic acid sequence of SEQ ID NO: 149, or a nucleic acid sequence that is at least 90% identical to SEQ ID NO:

149. Boosting with an immunogenic composition containing An immunogenic composition according to any one of claims 37 to 38, comprising the above.

40. The immunogenic composition according to any one of claims 37 to 39, wherein the viral vector in the basic composition is a Kali-mammalenavirus (also known as pitin de mammalenavirus or pitin de arenavirus) viral vector, and the viral vector in the reinforcement composition is a lymphocytic choriomeningitis mammalenavirus (LCMV) viral vector.

41. The immunogenic composition according to any one of claims 37 to 40, wherein the viral vector in the basic composition and the viral vector in the reinforcement composition are attenuated for replication.

Images